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ABSTRACT 
 
 Poor nutritional status is common and among the strongest predictors of mortality in 
patients undergoing maintenance hemodialysis (HD) treatment. Reduced dietary intake, 
especially on days in which patients undergo treatment, is one factor that contributes to this poor 
nutritional status. Providing nutritional supplements or allowing patients to eat during HD 
treatment can help restore dietary intake, improve nutritional status, and significantly reduce 
mortality in malnourished patients. However, in the United States this practice is frequently 
restricted due to concerns about patient safety. 
 To better understand practice patterns related to eating during HD treatment we 
conducted an international survey. We received 73 responses representing clinics in six 
continents. Among this cohort, 61 of 73 clinicians (85%) were at clinics that allowed patients to 
eat during treatment and 53 (73%) were at clinics that provided food during treatment. 
Interestingly, none of the nine clinics from North America provided food during treatment. In the 
second part of this survey, we asked the 61 clinicians who were at clinics which allowed patients 
to eat during treatment about their experience with the six most-cited reasons to restrict eating 
during treatment using a four point scale. Clinicians responded that they observed choking 
(98%), reduced Kt/V (98%), infection control issues (96%), spills or pests (83%), gastrointestinal 
issues (71%), and hypotension (62%) either “rarely” or “never.”   
 The results of our survey suggested that gastrointestinal (GI) issues were amongst the 
conditions most frequently attributed to eating during HD treatment. However, there have been 
no studies directly examining the effects of providing nutrition on these symptoms. One reason 
for this lack of data may have been the absence of a validated tool to measure GI symptoms. 
Therefore, we developed and validated a questionnaire to measure GI symptoms associated with 
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a single HD treatment. Following a brief face validation with renal dietitians, we recruited 50 
maintenance HD patients and administered our survey following a mid-week HD treatment. 
During the same treatment we measured dietary intake by diet recall. Three weeks later we 
repeated this process. In general, we found good agreement between items in each domain and 
repeatability among individual domains. Prevalence of GI symptoms during treatment (77.1%) 
was much higher than previously reported and associated with the intake of fat (r=.318, p = 
0.027) and fiber (.386, p = 0.007) during treatment.  
At the same time as our validation study, we also sought to determine the effect that 
liquid supplements had on the symptoms commonly associated with eating during treatment. We 
used a within-subjects design (n=8) to compare standard HD treatment (HD) to a standard HD 
treatment in which patients ingested 30 grams of whey protein starting 30 minutes into their 
treatment (HD + Protein). We found no interaction between groups in any hemodynamic variable 
(p>0.05). However, there was a main-effect of time for a reduction in SBP, decrease in heart 
rate, and a trend for a reduction in MAP. Furthermore, there was no difference in the reduction 
ratio of β2-microglobulin, reduction ratio of urea, GI symptoms, or symptomatic hypotension 
between the two treatments (p > 0.05 for all). These data suggest that 30 grams of whey protein 
by itself does not exacerbate symptoms during HD treatment.  
However, carbohydrates and lipids have been previously implicated as the primary cause 
of postprandial drops in blood pressure and GI symptoms during hemodynamic instability. 
Therefore, we applied the same within-subjects model to test for the effect of a renal specific 
mixed-macronutrient supplement. We baseline tested 11 HD patients to determine cardiovascular 
structure and function. Following baseline testing, we monitored a standard HD treatment (HD) 
and a standard HD treatment in which patients consumed a nutrition supplement (HD + ONS).  
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HD + ONS resulted in a trend for an increase in blood glucose (p = 0.061) compared to HD. 
Despite this increase in glucose, a potentially vasoactive compound, we found no interactions 
among any hemodynamic variable (p>0.05 for all) in the HD + ONS compared to HD. While 
there were no interactions, postprandial beat-to-beat cardiac output and heart rate were elevated 
in the HD + ONS group compared to the HD group (p < 0.05) over the 150 minutes following 
supplementation. In spite of these hemodynamic alterations, we found no statistical difference 
between any measure of treatment efficiency or GI symptoms between HD and HD + ONS (p > 
0.05 for all). When we compared the maximum change in BP following ONS with treatment 
characteristics, cardiovascular structure, and cardiovascular function, we found only baseline 
baroreceptor sensitivity was associated with the change in MAP (r=0.706, p=0.05). 
In conclusion, we tested the effects of two liquid nutritional supplements on three of the 
main reasons cited by clinicians to restrict intradialytic nutrition. We found no difference in 
blood pressure, treatment efficiency, or GI symptoms with either supplement. However, we did 
find an elevated cardiac output and heart rate following the consumption of a mixed-
macronutrient supplement. Future work should continue to evaluate factors related to safety of 
intradialytic nutrition, especially the effect of different supplements on local postprandial 
hemodynamics, gut barrier function, and intestinal ischemia. However, our data do not support 
the frequent practice of restricting intradialytic nutrition.  
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CHAPTER 1 
INTRODUCTION 
Nutritional status is among the strongest predictors of poor outcomes in HD patients 
independent of weather it is measured by dietary intake [1, 2], body size [3], biochemical 
indicators [4, 5], or more comprehensive scoring systems [6]. One factor that contributes to poor 
nutritional status in patients undergoing maintenance HD is inadequate dietary intake [7, 8]. This 
inadequate intake is further reduced on days in which patients undergo treatment [8]. Allowing 
patients to eat or consume nutritional supplements during a single treatment can help maintain 
intake [8, 9], attenuate inflammation [9], and prevent muscle catabolism [10-12]. Continuing to 
provide nutritional supplements during treatment improves nutritional markers in the blood  [13], 
body reserves [14-16], and subjective global assessment [15]. All of these improvements may 
contribute to the reduction in mortality that has been observed when providing intradialytic 
nutrition to malnourished patients [17, 18].  
Despite the well documented benefits, providing nutrition during HD treatment is 
controversial. Many reasons have been proposed to restrict intradialytic nutrition [19], but very 
few of these reasons have actually been examined [20]. This has led to clinic practices that vary 
widely throughout organizations, regions, and the world [21]. The most studied of the potential 
risks associated with eating during treatment is hemodynamic instability. Previous trials have 
produced mixed result, but in general have found a transient reduction in BP after eating that has 
not resulted in symptomatic hypotension [20]. However, these trials have also been surprisingly 
uniform in that they have enrolled hemodynamically stable patients and fed large, solid, mixed-
macronutrient meals.  
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Liquid nutritional supplements represent an alternative to solid meals. Among clinicians, 
there is a perception that these supplements may be less hemodynamically challenging and 
therefore, many clinics have adopted different policies related to providing intradialytic 
nutritional supplements as opposed to solid food. Certainly arguments could be made to support 
these notions, as liquid supplements cause gastric distension which results in a well-documented 
gastric pressor response that helps maintain postprandial BP. However, liquid supplements also 
empty more quickly from the stomach, which is a key determinant of both the magnitude and 
duration of postprandial drops in BP.  
Therefore, we set out to determine the effect of two different liquid nutritional 
supplements on symptoms commonly associated with eating during HD treatment. In our first 
study, we chose to use a supplement containing protein because of both its documented benefits 
when provided during HD and its smaller hemodynamic alteration compared to the other 
macronutrients. Due to previous reports demonstrating minimal hemodynamic changes following 
protein ingestion, we hypothesized that this supplement would not lead to changes in 
hemodynamics or symptoms compared to a standard HD treatment. In our second study, we 
chose to use a renal specific mixed-macronutrient supplement. These supplements have 
previously been shown to be the preferred supplements of maintenance HD patients. Given the 
addition of carbohydrates and lipids, we hypothesized that this would lead to a transient 
reduction in BP, but not be associated with increased symptoms. We believe that understanding 
the postprandial response, especially to different types of food and supplements, is an important 
step to the widespread utilization of intradialytic nutrition and the first step towards the 
development of standardized clinical recommendations for this important practice.  
 
3 
 
CHAPTER 2  
RETHINKING THE RESTRICTION ON NUTRITION DURING HEMODIALYSIS 
TREATMENT 
Introduction 
The annual mortality rate for maintenance hemodialysis (MHD) patients in the United 
States (U.S.) is nearly 20%, a rate that is higher than nearly every other industrialized country in 
the world [22]. This disparity in mortality rates has been attributed to many factors including, but 
not limited to, patient demographics and certain clinical practices. With reference to the latter, an 
obvious difference between hemodialysis (HD) treatment in the U.S. and elsewhere is that 
patients in the U.S. are often not allowed to eat while dialyzing. Providing nutrition during 
dialysis has been shown to be effective in improving whole-body protein balance and attenuating 
hemodialysis-related inflammation without obvious metabolic complications [19, 23].  Recent 
data also suggests that intradialytic nutrition supplementation is associated with better survival in 
MHD patients [17, 18].  
Despite its well-documented advantages, intradialytic feeding is heavily restricted in the 
U.S., primarily due to concerns that eating during HD may exacerbate hypotensive events during 
the treatment. Additionally, reduced dialysis efficiency and exacerbation of gastrointestinal 
symptoms are also frequently cited as reasons to restrict intake during HD (Table 1) [24-26]. 
These concerns, however, may be somewhat exaggerated and could be detrimental, as restricting 
nutrient consumption during HD contributes to increased protein breakdown [11, 27] and 
 
______________________________________________________________________________ 
Reprinted from Journal of Renal Nutrition, Volume 25, Authors: Kistler BM, Fitschen, P, Ikizler, 
T, and Wilund KR, Title: Rethinking the restriction on nutrition during hemodialysis treatment, 
Pages 81-87, Copyright (2015) with permission from Elsevier. 
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worsening nutritional status, further predisposing MHD patients to increased risk of morbidity 
and mortality [28]. 
 
Nutritional status is an important predictor of outcomes in MHD patients 
HD, while life-saving, is a highly catabolic condition. It is estimated that 18-75% of 
MHD patients may suffer from protein-energy wasting (PEW) [29]. MHD patients can lose 
between 1-3 kg of lean mass per year [30], leading to significant reductions in physical function, 
fitness, and activity [31]. This shift towards a frail phenotype with worsening nutritional status is 
also associated with reduced quality of life [32], increased hospitalizations [33], and mortality 
[34]. The relationship between nutrition status and outcome is consistent across a wide range of 
nutritional markers including biochemical indicators [4, 5, 35], nutritional intake [1, 2], and 
nutritional reserve (fat and lean mass) [28]. These findings suggest that nutrition status may be 
an appropriate target to improve outcomes in this population.  
 
Recommended protein and energy intake in MHD patients  
The Kidney Disease Outcomes Quality Initiative (KDOQI) guidelines recommend 
increased caloric and protein intakes (35 kcal/kg/day and 1.2g/kg/day, respectively) for MHD 
patients [36]. These elevated intakes may be difficult for patients to reach due to a variety of 
barriers including dietary restrictions, anorexia, and socio-economic limitations [37]. Indeed, 
many patients fail to comply with these recommendations as evidenced by large clinical trials, 
such as the HEMO study, in which cohorts were significantly below the KDOQI guidelines [38]. 
Furthermore, research has shown that dietary intake is lower on treatment days as compared to 
non-treatment days. This is especially true in patients who do not eat during their treatment [38], 
5 
 
suggesting that the intradialytic window may be an important therapeutic target to improve 
dietary nutrient intake. 
 
Eating during dialysis is restricted in most US clinics 
Despite the benefits specific to providing intradialytic nutrition (reviewed in [19, 23]), 
eating during HD has remained a topic of debate for many years within the field of nephrology 
[24-26]. Eating during HD treatment is restricted in many clinics in the U.S., despite being 
allowed or even encouraged, in many other countries. Surprisingly, very little research has 
assessed many of the proposed risks of eating during dialysis (Table 1). Instead, many of the 
concerns are based on anecdotal evidence from clinical practice, which may be subject to impact 
bias and should be investigated in well-controlled trials. The following sections will highlight the 
current state of evidence regarding the proposed risks of eating during dialysis, with special 
attention given to effects on blood pressure regulation and intradialytic hypotension, as this is a 
primary reason cited for the eating restrictions.  
 
Table 1. Proposed Advantages and Disadvantages to Intradialytic Nutrition 
Proposed Advantages Proposed Disadvantages 
Reduced Mortality 
Improved nutritional status 
Patient adherence and satisfaction 
Educational opportunity 
Improved blood glucose control 
Provide more appropriate food choices 
Reduced inflammation 
Postprandial hypotension 
Reduction in efficiency 
Gastrointestinal symptoms 
Hygiene 
Increased staff burden 
Financial constraints 
Aspiration 
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Intradialytic hypotension: A common complication of HD treatment 
 Intradialytic hypotension (IDH) is the most common adverse event during HD treatment, 
with an estimated prevalence of 5 to 40% of all treatments [39-42]. IDH may be either 
symptomatic or asymptomatic. Symptomatic IDH generally meets three criteria: 1) an abrupt fall 
in blood pressure (BP); 2) symptoms such as cramping, headaches, nausea and vomiting; and 3) 
requires medical intervention [43]. Symptomatic hypotension is a major concern because it is 
both uncomfortable and dangerous for the patient.  Oftentimes, symptomatic hypotension 
requires the ultrafiltration rate to be decreased, or very rarely the treatment to be stopped 
altogether.  Interventions to treat symptomatic IDH include administration of mannitol and 
saline, which increase the osmolarity of the blood and expand plasma volume. These 
interventions, however, cause significant thirst between treatments, contributing to high 
interdialytic fluid gains that further increase the risk of  IDH in the subsequent HD treatment 
[44]. Chronic fluid overload during the interdialytic period and hypotension during treatment are 
believed to contribute to a gradual impairment of cardiac function [45]. These factors may 
contribute to the strong relationship between IDH and poor outcomes in MHD patients [46].  
 
Eating during dialysis and blood pressure  
There is a concern that eating during HD may exacerbate the decline in BP that typically 
occurs during treatment, leading to greater incidence of IDH [47].  While eating is typically not 
associated with a drop in blood pressure in healthy young adults [48], in certain populations such 
as those with insulin resistance, the aged, or those with autonomic dysfunction, eating may result 
in a postprandial drop in BP [49].  Epidemiologic studies have identified a number of risk factors 
that may contribute to excessive drops in BP following eating (reviewed in [50]). These factors 
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include excessive blood pooling in the splanchnic region, reduced baroreflex function, 
inadequate sympathetic neural drive, release of vasodilatory molecules during digestion, and 
hypovolemia. Any of these factors may contribute to a drop in BP following eating, and are 
primary concerns for potential causes of IDH following intradialytic nutrition.   
 
Studies examining the effect of eating during HD treatment on BP and hemodynamics 
Observational studies 
 Two observational studies have reported on the association between intradialytic eating, 
drinking, and BP. The largest study was a retrospective chart review of habitual intake and BP 
over three treatments in 126 stable MHD patients [51]. No correlation was found between oral 
intake and any measure of BP. Furthermore, there was no difference in oral intake between days 
where IDH occurred or did not occur (p=0.93). In contrast, a second observational study 
investigated the relationship between habitual nutrient intake during MHD and IDH in 23 
patients over 166 total treatments [52]. Although the overall incidence of events was quite low 
(13 total mannitol events), hypotension (SBP<90 mm Hg) occurred more often when patients 
consumed more than 200 kcal during treatment (p<0.001), and the use of mannitol was higher in 
the group that consumed greater than 200mL of fluid (p<0.014).  Despite these hemodynamic 
differences there was no difference in symptoms such as cramping.  These equivocal findings 
may be the result of many differences in methodology.  Most notably, the latter investigation did 
not select stable patients and may highlight that food intake is better tolerated in those patients 
who are stable.    
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Interventional studies 
The suggestion that eating during MHD treatment results in a significant reduction in BP 
was first put forward 3 decades ago by Sherman et al [53] who studied 9 non-diabetic MHD 
patients prospectively over 125 dialysis treatments. In half of these treatments (n=62), patients 
were given a standard meal halfway through their dialysis treatment. One year later, Zoccali and 
colleagues undertook a similar study in 13 patients [54]. Both of these studies found an 
acceleration in the drop in BP, a transient reduction in BP, and an increase in symptomatic 
hypotension in the time following the meal.  However, the applicability of these studies to 
current treatment may be limited by differences in treatment parameters including dialysis 
membrane, dialysate, and the use of acetate as a buffer, which has been shown to increase the 
risk of developing hypotension [55].  
Following this initial work demonstrating postprandial reductions in BP during HD 
treatment, work shifted towards examining the mechanism for these changes. Given the 
compounding influence of eating and ultrafiltration on blood volume, hypovolemia has been a 
common target.  Sivalingham and colleagues gave 20 stable MHD patients a standard meal 45 
minutes into their HD treatment. The rate of change in relative blood volume (RBV) increased in 
the postprandial state compared to pre-meal values. These changes coincided with a significant 
reduction in mean arterial pressure (MAP) 30 minutes after food intake (91 ± 19 vs. 86 ± 20mm 
Hg, p = 0.04). Similarly, Shibagaki and colleagues found a postprandial reduction in RBV 
preceding changes in BP suggesting a possible role of RBV and hypovolemia in the postprandial 
drop in BP [56].  
The Shibagaki study also allowed a unique opportunity to compare the effects of patient 
position on hemodynamic response [56]. Sixteen of 21 patients received a standard meal during 
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dialysis in the supine position and six in the seated position (one received in both). RBV dropped 
less in patients who were in the supine compared to the seated position (Seated -28.21±2.41 vs. 
Supine -13.99±0.91%/hr). Similarly, systolic blood pressure (SBP) and diastolic blood pressure 
(DBP) dropped compared to the pre-meal values in patients who received the meal in the seated 
position (152/85 to 143/79 mmHg), but only DBP was reduced in patients in the supine position 
(138/78 to 137/71 mmHg).  Although differences in RBV and BP in patients in the supine 
position were minimal compared to those in the seated position, this observation suggests that 
reductions in venous return may play a role in the drop in BP some patients experience following 
eating and warrants further examination.  
Barakat and colleagues further examined the mechanism behind hemodynamic 
adaptations to food ingestion [57]. To accomplish this, they maximized hypovolemic stress by 
distributing ultrafiltration over only the first two hours of treatment; feeding a standard meal 
after the first hour.  Within this context, they found eating caused a significant reduction in MAP 
as a result of reduced systemic vascular resistance and lack of increase in cardiac output. These 
findings supported  a previous hypothesis that the drop in blood pressure as a result of 
intradialytic feeding was the result of increased blood flow to the digestive system, lowering of 
peripheral resistance, and lack of cardiac compensation [58]. However, these mechanistic studies 
also raise many important questions including the influence these adaptations have on central 
BP, symptom development, and the influence of meal or supplement composition on these 
hemodynamic adaptations.   
Finally, in recent years two larger studies have emerged examining the hemodynamic 
response to eating during HD [59, 60].  Kara and Acikel fed 25 stable patients a standard meal 
and witnessed a transient reduction in BP but no difficulties with symptomatic hypotension.  
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Similarly, Müller-Deile and colleagues conducted a study to examine the influence of eating 
during HD on hemodynamics and treatment efficiency [59].  Forty stable MHD patients were fed 
a standard meal during treatment. They found no reduction in SBP, DBP, or MAP following 
meal ingestion (p>0.05 for all vs BP before eating) further suggesting that eating is generally 
well tolerated, especially in stable MHD patients. Future work should attempt to determine what 
differentiates patients who may experience a drop in BP following eating.   
 
The effect of eating during treatment on solute removal 
 Another proposed consequence arising from eating during treatment is a reduction in the 
efficiency with which solutes are removed during treatment.  Two main mechanisms have been 
proposed to explain why intradialytic food consumption may reduce the efficiency of HD 
treatment [60]. The first, although not documented in the literature, is that patients will 
discontinue treatments early due to discomfort caused by the reduction in BP. This shortened 
treatment time would lead to a reduction in solutes removed by dialysis. The second mechanism 
proposes a reduction in solute removal due to sequestration of blood in the digestive tract, 
minimizing the blood available to be dialyzed and reducing the concentration gradient between 
the blood and dialysate.  
 
Studies examining the effect of eating on dialysis efficiency 
Several studies have examined the influence of eating before or during HD on treatment 
efficiency. Singri and colleagues compared the efficiency of a single dialysis treatment following 
a three hour fast to that of a meal two hours prior to the start of dialysis [61]. The meals were 
variable, but all contained at least 0.4 g of protein per kilogram of body weight. They found that 
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efficiency, as measured by urea reduction ratio (URR) and single pool Kt/V, was not reduced as 
a result of eating a meal prior to the start of the treatment. Eating prior to the start of HD is 
unlikely to lead to the circulatory changes or early treatment termination hypothesized to 
contribute to a reduction in efficiency.   
To more appropriately address these concerns, two studies have measured the effect of 
intradialytic food consumption on efficiency using urea kinetics.  Kara and Acikel examined the 
effects of eating during dialysis on treatment efficiency (N = 25) [60] by comparing a standard 
HD treatment with one where patients were given a standard meal. Similarly, San Juan 
Miguelsanz et al. [62] assessed patients during standard dialysis in which they were allowed to 
eat, followed by restricting intradialytic food intake the following week.  In both the study by 
Kara and Acikel (URR 67.8±6.1 vs. 72.1±.0, p<0.001; Kt/V 1.4±0.2 vs. 1.6±0.2, p<0.001) and 
San Jaun Miguelsanz (URR (71.5±5.92 vs. 73.5±6.61, p=0.057 and Kt/V 1.54 vs. 1.65, p < 0.05) 
efficiency was reduced in the treatment in which patients ate. However, the interpretation of 
these studies is limited by the possible confounding effects of protein metabolism on estimated 
urea removal. In fact, it has been hypothesized that if urea modeling was applied to this data to 
account for the protein patients consumed, the efficiency of these treatments may actually have 
improved [63].   
Using different methodology, Müller-Deile and colleagues further examined the effect of 
eating during HD on treatment efficiency [59].  They continually monitored treatment efficiency 
by both UV absorbance and dialysate collection. Efficiency, as measured by UV absorbance, but 
not dialysate clearance, was transiently influenced by eating.  Potential explanations for the 
transient reduction in efficiency with UV absorbance include increasing solute appearance due to 
rapid absorption or release from other compartments. The combination of results from these 
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studies suggest that observed reductions in measurements of efficiency may be the result of 
increased appearance rather than reduced clearance, and the clinical significance of these 
reductions is limited. This argument is furthered by recent evidence from our laboratory 
suggesting that reduced treatment efficiency is not commonly experienced by practitioners who 
allow patients to eat during treatment (Kistler et al., manuscript in preparation).   
 
Studies examining the effects of eating during HD on GI symptoms and other concerns 
 Of the remaining concerns to restrict intradialytic eating (Table 1), gastrointestinal (GI) 
symptoms are the most frequently cited by practitioners. MHD patients have a greater prevalence 
of GI symptoms than the general population [64, 65], and these symptoms are inversely 
associated with serum albumin and quality of life [64]. Nausea and vomiting are common in 
patients with kidney disease possibly due to delayed gastric emptying [66], although many other 
factors are likely to contribute. GI symptoms, including nausea, are thought to occur acutely 
during 10-15% of all treatments [67-69]. Nutritional supplementation studies that have tracked 
GI symptoms have reported incidences similar to [14, 70], or below [71] these estimates. 
However, to our knowledge there are currently no studies directly examining the effects of eating 
during HD on GI symptom amount or severity and trials are needed to determine if eating 
increases the incidence of these symptoms.  
 
Summary of Current Findings 
Hemodynamic complications are the most commonly cited reason to restrict intradialytic 
nutrition. Previous studies have demonstrated that eating during treatment causes a transient drop 
in BP. However, there is limited evidence that this transient drop in BP translates to clinically 
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significant increases in symptomatic hypotension in patients undergoing MHD, especially in the 
era of bicarbonate-based dialysate [59]. This observation is further supported by the large 
number of intradialytic supplementation studies that have not observed hemodynamic 
complications. Many questions related to hemodynamic stability following intradialytic eating 
remain unanswered, such as understanding the role of meal composition and the presence of 
underlying cardiovascular complications on the risk of developing IDH. Additional research is 
needed to help outline best practices and to determine ways to minimize patient risk.  
Treatment efficiency is the most studied of the remaining concerns about eating during 
HD.  However, many of these studies are confounded by the effect of protein metabolism on urea 
kinetics. Furthermore, the modest and sometimes transient reductions observed in treatment 
efficiency may not be clinically relevant. Therefore, it remains unclear if eating has any 
significant influence on treatment efficiency. To our knowledge, other arguments against eating 
during dialysis treatment such as food safety, staff burden, pest control, and choking or 
aspiration have not been studied. Future studies should address these issues so practitioners can 
make more informed decisions regarding patient feeding practices during treatment.   
 
Conclusions 
 MHD treatment is a catabolic procedure with significant adverse consequences including 
muscle wasting, reduced quality of life, and a number of metabolic alterations. Recent evidence 
shows intradialytic nutrient supplementation represents a clinically and financially feasible 
strategy to improve nutrition status. Available data indicate that while eating during HD 
treatment does generally cause a transient reduction in BP, it is tolerated by a vast majority of 
patients without significant clinical consequences. While further research may demonstrate 
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strategies to reduce the potential risks associated with eating during treatment, the widespread 
use in multiple countries without reports regarding its complications suggests that intradialytic 
nutrition is an appropriate strategy to improve clinical outcomes in a large proportion of the 
MHD patient population who can tolerate it. 
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CHAPTER 3  
TO EAT OR NOT TO EAT-INTERNATIONAL EXPERIENCES WITH EATING 
DURING HEMODIALYSIS TREATMENT 
Introduction 
 Maintenance hemodialysis (HD) is a highly catabolic condition. Poor nutritional status is 
common in HD patients [29] and is associated with reduced quality of life [32], increased 
hospitalizations [33], and increased mortality [34]. Providing patients with supplemental 
nutrition during a single HD treatment increases skeletal muscle protein synthesis, reduces 
catabolism, and improves net protein balance [11, 12, 72].  Long-term provision of nutrition 
during HD treatment has been shown to increase nutritional indicators such as albumin [13], lean 
mass [16], and subjective global assessment [15] as well as quality of life [73]. These 
improvements in nutritional status may contribute to the recent observation that intradialytic oral 
nutrition supplementation programs are associated with significant reductions in mortality [17, 
18].   
Despite these benefits, many clinics do not allow patients to eat during HD treatment. 
Many reasons have been proposed to restrict patients from eating during HD, including 
hemodynamic instability, choking risk, and reductions in dialysis efficiency, among others [19, 
24, 25]; however, these concerns are primarily anecdotal as there is little evidence in the 
published literature supporting them. The lack of research on this topic may contribute to varying 
clinical practices [74]. Furthermore, differences in clinic practices on eating during treatment 
______________________________________________________________________________ 
Reprinted from Journal of Renal Nutrition, Volume 24, Authors: Kistler BM, Benner, D, 
Burgess, M, Stasios, M, Kalantar-Zadeh, K, and Wilund KR, Title: To eat or not to eat: 
international experiences with eating during hemodialysis treatment, Pages 349-352, Copyright 
(2014) with permission from Elsevier. 
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have been suggested to contribute to the global disparities in albumin and other nutrition 
indicators [19, 75]. Describing international clinic practices is an important step to better 
understand worldwide differences in nutritional outcomes and determine best practices. 
Therefore, we set out to perform a survey to describe international practices on eating during 
treatment and to provide insight into clinical experiences with eating during treatment.   
  
Methods  
 We developed an 11 item survey about clinic practices and clinician experiences related 
to eating during HD treatment. This survey was developed based on a combination of clinical 
experience and review of the literature [19, 24, 25]. Demographic data for each participant was 
also collected. The survey was distributed to attendees during the 2014 International Society of 
Renal Nutrition and Metabolism Conference in Wurzburg, Germany [76]; all attendees were 
encouraged to respond. Collected surveys were analyzed and entered into SPSS version 22 
(Chicago, IL). Partial responses were included in the overall analysis. Data are reported as the 
number of respondents and the percent of categorical responses. A chi-square test (χ2) was used 
to determine practice differences between clinic settings. Significance was set using an alpha of 
0.05. However, no additional statistical comparisons were performed due to the limited number 
of responses. Finally, qualitative data were analyzed, clustered, and summarized.   
 
Results 
 We received 73 responses from six continents (Africa (3, 4.1%), Asia (7, 9.6%), 
Australia (5, 6.8%), Europe (39, 53.4%), North America (9, 12.3%), South America (10, 
13.7%)). Clinicians who responded to the survey were dietitians (71.2%), nephrologists (26.0%), 
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or clinical researchers (2.7%) who worked in units housed within a hospital (63.0%), outpatient 
clinic (45.2%), and/or an academic setting (16.4%).   
Clinic practices for eating during hemodialysis treatment are summarized in Figure 1. 
Fifty-three clinics (72.6%) served food other than supplements during HD. Forty-nine of the 53 
clinics who served food during treatment (92.5%) provided food at no cost to the patient. 
However, none of the nine clinics from North America provided food during treatment. Clinics 
that were in a hospital setting were more likely to provide food to patients during treatment than 
those that were not associated with a hospital (χ2 = 3.84, p = 0.05). Qualitative analysis of 
clinician responses showed that clinics providing food were generally providing full meals that 
tended to be high in carbohydrates. In addition, tea or coffee was often included as a beverage. 
Forty-seven clinicians responded that their clinics (64.4%) provided supplements during 
treatment. Forty-three of the 47 (91.5%) provided these supplements at no cost to the patient. 
Outpatient clinics were less likely to provide nutritional supplements during treatment compared 
to clinics who were not described as outpatient (χ2 = 4.35, p < 0.04). Clinics tended to provide 
patients with liquid as opposed to solid supplements. These supplements were most often 
commercially-available mixed macronutrient supplements.   
We also asked clinicians about their experiences with eating during treatment. When 
asked whether four specific factors influenced their decision to allow patients to eat, clinicians 
responded that they allowed patients to eat in order to provide additional energy (88.7%), 
teaching opportunities (46.8%), better control of blood glucose (32.3%), and difficulty enforcing 
a no eating policy (16.1%). Additionally, clinician open-ended responses included: patient 
quality of life, providing protein, barriers to intake outside of the clinic (i.e., lack of cooking 
skills, transport time, socio-economic limitations, etc.), clinic culture, and nutrient timing. 
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Finally, we asked clinicians about six commonly-cited reasons to restrict feeding during HD. 
Clinician responses are summarized in Table 2. In general, clinicians did not frequently 
experience these proposed consequences of eating during treatment. In addition to these 
commonly cited reasons, clinicians also indicated that staff workload, difficulty overcoming 
clinic culture, cost, and patients’ forgetting binders as reasons to restrict eating during HD 
treatment. 
Table 2. Clinician experiences with six commonly cited reasons to restrict eating during 
hemodialysis treatment.  
 
 Never  Rarely Sometimes Often 
Postprandial Hypotension (n=53) 18 (34.0) 15 (28.3) 18 (34.0) 2 (3.8) 
Gastrointestinal Symptoms (n=52) 14 (26.9) 23 (44.2) 15 (28.8) 0 (0.0) 
Reduced Treatment Efficiency (n=45) 42 (93.3) 2 (4.4) 1 (2.2) 0 (0.0) 
Spills or Pests (n=46) 31 (67.4) 7 (15.2) 5 (10.9) 3 (6.5) 
Choking (n=46) 39 (84.8) 6 (13.0) 1 (2.2) 0 (0.0) 
Infection Control Issues (n=46) 42 (91.3) 2 (4.3) 2 (4.3) 0 (0.0) 
 
Discussion 
 We conducted a survey examining the practices and experiences of clinicians related to 
eating during HD treatment at the International Society of Renal Nutrition and Metabolism 
Conference in Wurzburg, Germany. Our primary findings from this survey include the 
following:  1) eating during dialysis is commonly allowed and frequently encouraged by clinics 
throughout most of the world; 2) many clinics provide food and supplements to patients at no-
cost; 3) providing additional energy appears to be the primary reason that clinics allow or 
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encourage patients to eat during treatment; and 4) many of the proposed negative sequelae of 
eating during HD are not commonly observed in clinical practice.  To our knowledge this is the 
first published study to describe international practices related to eating during treatment.   
 Understanding the variability in clinic guidelines is an important step to outlining best 
practices. We observed that most clinics around the world allow, encourage, and in many cases, 
provide food at no-cost to patients. However, none of the nine clinics from North America 
provided patients with food. This supports previous reports indicating that practices related to 
eating during treatment in North America, particularly the U.S., appear to be more restrictive 
[19]. While the current study is underpowered to make statistical comparisons between 
continents or countries, this observation deserves further examination. Though speculative, this 
difference in clinical practice may contribute to the observation that patients’ albumin levels tend 
to be lower, and mortality rates higher, in the U.S. compared to the rest of the world [75].  
 Another interesting observation was that the food being provided to patients was high in 
carbohydrates. This is important given our finding that approximately 37% of clinicians have 
observed hypotension at least “sometimes.” Carbohydrates have been shown to lead to a 
disproportionate postprandial drop in blood pressure compared to the other macronutrients [77], 
although this effect has not been demonstrated in patients undergoing HD. In addition, protein 
appears to be more effective at preventing HD-associated catabolism and inflammation [11, 12] 
and may lead to fewer hemodynamic complications. Further research may be warranted to 
determine the optimal food choices during HD treatment.   
 We also asked clinicians about their experiences with patients eating during HD 
treatment. These clinical experiences contribute important evidence to the debate within the 
nephrology community about the best practices related to eating during treatment [19]. Providing 
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additional energy was the primary reason that clinics allowed patients to eat during treatment. 
When asked about six commonly-cited arguments for restricting eating during HD treatment, 
clinicians reported that the majority of these concerns occurred “rarely” or “never.” The most 
frequently reported consequence of eating during treatment was intradialytic hypotension. This is 
consistent with previous observations that eating during treatment causes a transient reduction in 
blood pressure, but is generally well accepted in stable patients (Kistler et al., manuscript in 
preparation). Describing the frequency and individual circumstances with which these symptoms 
occur will help clinicians make informed decisions regarding practices in this controversial area.   
 A primary weakness of this study was that the data was obtained from a convenience 
sample of clinicians attending a renal nutrition conference. These practitioners are likely to have 
greater interest in nutrition and may have more progressive policies in their clinic related to 
eating during HD treatment. In addition, this survey was written in English which may have 
limited the participation of non-native English speaking participants. We also did not receive an 
adequate number of responses to statistically compare continents. Despite this limitation, the 
group as a whole has provided valuable insight into clinical experiences with eating during 
treatment. Additionally, this research has raised important questions about differences in practice 
around the world and how these may contribute to global disparities in nutritional status and 
outcomes.  
In summary, our results indicate that eating is common during treatment in many 
countries around the world, disparities may exist in global practices, and most of the proposed 
negative sequelae of eating during HD are not commonly observed in clinical practice. These 
data describe current nutrition practices, provide a potential contributor to global differences in 
albumin, and highlight the need for more research to inform decisions regarding eating during 
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HD. Specifically, future research should be conducted to further characterize and evaluate 
international differences in eating practices, to examine the prevalence and severity of proposed 
consequences associated with eating during treatment, and to find ways to minimize patient risk.   
Practical Applications  
 This study suggests that many of the proposed negative consequences associated with 
eating during treatment are not commonly observed by practitioners in the clinical setting. This 
observation should provide insight into current practices and highlight the need for future 
research in this controversial area of practice.    
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CHAPTER 4 
A SCALE TO MEASURE GASTROINTESTINAL SYMPTOMS ASSOCIATED WITH A 
SINGLE HEMODIALYSIS TREATMENT: VALIDATION AND ASSOCIATION WITH 
INTAKE DURING TREATMENT 
 
Introduction 
 Gastrointestinal (GI) symptoms are a common problem in ESRD patients [64, 65] and are 
inversely associated with serum albumin and quality of life [64].  Many factors may contribute to 
the high prevalence of GI symptoms in ESRD patients including uremia, delayed gastric 
emptying, and medications [66]. In addition to the uremic syndrome, the dialysis procedure itself 
may exacerbate these symptoms. Patients undergoing hemodialysis (HD) have significantly more 
GI symptoms than patients undergoing peritoneal dialysis [78]. These differences are especially 
pronounced in relation to abdominal pain, diarrhea, and constipation; symptoms that are 
consistent with the acute development of hypotension and mesenteric ischemia [79]. 
Furthermore, GI symptoms are among the most common complications of HD treatment [67-69] 
suggesting that these acute GI disturbances may contribute to the chronic differences in GI 
symptoms between dialysis modalities and therefore may be an important target for intervention.  
 Despite these observations, there is limited data on GI symptom development during HD 
treatment. Previous data on this topic has been almost exclusively based on single-item questions 
which can be unreliable [80] and limited in scope to questions about nausea [67-69]. 
Furthermore, there is a lack of data on the relationship between different treatment practices and 
GI symptom development. One such practice, eating during treatment, has frequently been 
restricted in part due to the hypothesis that it may contribute to GI symptom development [19]. 
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However, there are no trials specifically examining the relationship between eating during HD 
treatment and GI symptom development. A tool specifically designed to measure GI symptoms 
associated with a single HD treatment may add to the depth of knowledge on this topic and allow 
for the comparison of treatment practices. Therefore, the purpose of this study was to develop 
and validate a tool to measure acute GI symptoms associated with a single HD treatment and to 
assess the relationship between GI symptoms and intradialytic nutrient intake in maintenance HD 
patients.  
 
Methods 
 We modified the American version of the Gastrointestinal Symptom Rating Scale 
(GSRS) [81] to measure GI symptoms associated with a single HD treatment. The GSRS 
contains 15 questions in five domains (Abdominal Pain, Reflux Syndrome, Indigestion 
Syndrome, Diarrhea Syndrome, and Constipation Syndrome) scored on a seven point Likert 
scale (1=no symptoms and 7=very severe symptoms, Appendix 1). This version was modified by 
changing the wording of the questions within three domains (Abdominal Pain, Reflux Syndrome, 
and Indigestion Syndrome) to ask specifically about the time during a single HD treatment. 
Wording of the remaining two domains (Diarrhea Syndrome and Constipation Syndrome) were 
altered to ask patients about the time immediately following the specific HD treatment until the 
start of the following treatment.  
 We sent this modified version of the GSRS to five renal dietitians around the country for 
comment. Comments received more than once were discussed by the authors and considered for 
inclusion. Based on these expert comments, one additional modification to the wording in the 
questions was adopted.  
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Following this initial validation, we recruited 50 maintenance HD patients from clinics in 
central Illinois. One patient received a kidney transplant and one patient was unavailable for 
follow-up, leaving us with 48 HD patients completing all time points. At the end of a mid-week 
HD session, patients were asked about the symptoms they experienced (Abdominal Pain, Reflux, 
and Indigestion) during that specific treatment. During this same HD treatment, dietary intake 
was measured with a diet recall using the USDA 5-pass method along with visual inspection of 
items including cups and wrappers. At the start of the following treatment (48-72 hours later), 
participants were asked about symptoms from the final two domains (diarrhea and constipation) 
that they had experienced since the end of the previous treatment. Three weeks later this protocol 
was repeated to determine the repeatability of measures.  
 Data were entered into SPSS version 22. Internal consistency of each of the five domains 
was analyzed using Cronbach’s alpha. To determine repeatability, the correlations between GI 
symptom domains during the first and second treatment were analyzed using Pearson 
correlations. Prevalence of GI symptoms associated with a single HD treatment was determined 
by the proportion of participants with an average score greater than 1 on all of the questions 
within an individual domain of the first GSRS. GI symptoms in patients who ate during 
treatment (Average energy intake > 0 kcal) and those who did not eat during treatment were 
compared using independent samples t-test. Finally, the GSRS and dietary recall from the first 
and second treatment were averaged and the relationship between nutrients of interest and GI 
symptoms were determined using additional Pearson correlations. When outliers were present, 
we re-ran our correlations after removing outliers. Outliers were identified by the method 
suggested by Hoaglin [82]. In short, we extended the values at the 25
th
 and 75
th
 percentile by a 
25 
 
value 2.2 times the difference between the values at each of those quartiles. Significance for all 
analyses was set at an alpha of 0.05.  
 
Results 
 Forty-eight HD patients completed the entire study protocol and were included in the 
analysis (Table 3). Internal consistency and repeatability of the five domains are presented in 
Table 4. The internal consistency of the indigestion domain was improved by removing the 
question on burping. Therefore, the burping question was removed for all subsequent analyses.   
 
Table 3. Demographics for maintenance hemodialysis patients included in validation study.  
Demographics Value 
Age (Years) 56 ± 13 
Vintage (Months) 53 ± 59 
Gender (Male/Female) 30/18 
Race (%) 
     African American 
     Caucasian 
 
54.2 
45.8 
Hispanic (%) 8.3 
Diabetes (%) 54.2 
Smoke (%) 20.8 
Digestive Disorder (%) 18.8 
 
 
The prevalence of GI symptoms during a single HD treatment (generalized score greater 
than 1) was 54.2% (mean generalized score, 1.60 ± 0.74), 43.7% (1.48 ± 0.67), and 6.2% (1.07 ± 
0.31) for the abdominal pain, indigestion, and reflux domains respectively. In the time following 
a specific mid-week HD treatment, 41.7% (1.73 ± 1.24) and 45.8% (1.72 ± 1.09) reported a 
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generalized score greater than 1 for the diarrhea and constipation syndrome respectively. 
Combined 77.1% of HD patients experienced symptoms in at least one domain. However, the 
severity of symptoms was quite low with a mean score of less than 2 for all domains.  
 
Table 4. Reliability and repeatability of the GSRS to measure acute gastrointestinal symptoms 
associated with a single hemodialysis treatment.  
 
Scale Cronbach’s 
Alpha 
Correlation between repeated 
measures (p – value) 
Abdominal Pain .676 0.329 (0.022) 
Indigestion Syndrome .515 0.437 (0.002) 
Reflux Syndrome -.052 0.708 (<0.001) 
Diarrhea Syndrome .852 0.459 (0.001) 
Constipation Syndrome .778 0.645 (<0.001) 
Indigestion (Burping 
Removed) 
.631 0.415 (0.003) 
 
  
There was no significant difference in GI symptoms (P>0.05 for all) among patients who 
ate (n=32) versus those who did not eat (n=16) during treatment. However, there were significant 
correlations between dietary intake during treatment and GI symptom domains (Table 5), 
including correlations between the intradialytic intake of fiber, fat, and the severity of indigestion 
during the treatment (Figure 1). However, when outliers for fat and fiber intake were removed, 
these correlations were no longer significant (p>0.05).  
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Table 5. Average dietary intake during hemodialysis treatment and its association with 
gastrointestinal symptom severity measured by the GSRS.  
 
Nutrient Amount 
Stomach 
Pain 
Indigestion 
Syndrome 
Reflux 
Syndrome 
Diarrhea 
Syndrome 
Constipation 
Syndrome 
Energy  
(Kcal) 
112.72 ± 
158.52 
0.060 0.237 0.056 0.024 0.021 
Protein (g) 6.97 ± 
8.84 
-0.046 0.162 0.070 0.134 0.124 
Carbohydrate 
(g) 
14.57 ± 
22.62 
0.082 0.192 0.050 -0.025 -0.056 
Fat (g) 3.25 ± 
5.68 
0.050 0.318* 0.049 0.016 0.075 
Sodium (mg) 121.60 ± 
329.83 
0.078 0.208 -0.027 0.078 -0.19 
Fiber (g) 0.38 ± 
0.81 
0.132 0.386* 
 
0.028 0.076 0.135 
Sugar (g) 8.06 ± 
13.21 
0.033 0.075 0.035 -0.116 -0.136 
Fluid (g) 207.09 ± 
171.16 
0.130 0.148 -0.096 -0.087 -0.047 
*p<0.05 
 
Figure 1. Association between intake of nutrients and severity of indigestion during 
hemodialysis treatment. 
 
a.       b. 
 
 
Relationship between mean fat (a) and fiber (b) intake during hemodialysis treatment and the 
severity of indigestion experienced during hemodialysis treatment.  
 
 
28 
 
Discussion 
 We modified a version of the GSRS to measure GI symptoms associated with a single 
HD treatment. In general, this modified tool was internally consistent and repeatable in this 
population of maintenance HD patients. When we used these multi-item scales to measure GI 
symptoms associated with a single HD treatment, we found the prevalence of GI symptoms 
during treatment to be higher than previously reported. Although GI symptoms were quite 
prevalent, the severity of these symptoms was low. Finally, we found that the consumption of fat 
and fiber during HD treatment was associated with GI symptom severity.  
 In general, we found good agreement between the individual items within each domain in 
our modified version of the GSRS. The one exception was the reflux domain. This was likely 
due to the small number of patients (6.2%) who experienced reflux during treatment and may not 
speak appropriately to the level of agreement between items. One possible explanation for the 
low number of patients experiencing reflux is that all of the patients in the current trial were 
seated during treatment, which may reduce reflux [83]. Given the relatively high prevalence of 
reflux in the HD population (24.2%) [78], it is likely that it may be more prevalent in clinics 
were HD is performed in a different position. Similar to the data on agreement, we also found 
significant correlations between repeated measures among each of the domains. Combined these 
findings suggest that our modified version of the GSRS is an internally consistent and reliable 
tool for measuring GI symptoms associated with a single HD treatment.  
 The development of GI symptoms is a frequent complication of HD treatment. Previous 
trials have found that patients develop symptoms in approximately 10-15% of all HD treatments. 
However, these trials have relied on single item questions and have primarily asked only about 
the development of nausea. Similar to these previous trials, we found that approximately 16% of 
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patients experienced nausea during a single HD treatment. However, when we used a multi-item 
tool to ask about symptoms within five domains associated with a single treatment, we found that 
77.1% of HD patients experienced symptoms in at least one domain. This is a rate considerably 
higher than previous reports. Furthermore, the prevalence and severity of acute symptoms 
measured over a single HD treatment were quite similar to previous studies which have asked 
patients about their average symptoms over the preceding two weeks [78], suggesting that these 
acute symptoms may contribute to chronic GI problems. Given the strong relationship between 
GI symptoms and quality of life, future work should examine ways to minimize GI symptom 
development during HD treatment.  
 The possibility that eating during HD treatment may exacerbate GI symptoms is 
frequently used as an argument against allowing patients to eat during HD treatment [19-21]. In 
the current study, we found no difference in GI symptoms among patients who ate versus those 
who did not eat during treatment. However, when we looked at the relationship between the 
intake of nutrients and GI symptom severity, we found both fat and fiber intake during treatment 
to be associated with greater indigestion. These relationships did not remain significant after the 
exclusion of outliers suggesting that the intake of large amounts of these nutrients may be 
undesirable. While the relationship between fiber and indigestion is well documented [84], the 
relationship between fat intake and these symptoms is more surprising. However, in 
hemodynamically unstable patients lipids are thought to disproportionately contribute to the 
postprandial development of intestinal ischemia [85]. Therefore, the safety of lipid intake during 
HD treatment is a topic that warrants future research.  
 In conclusion, the modified version of the GSRS appears to be a reliable tool for the 
measurement of GI symptoms associated with a single HD treatment. The development of GI 
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symptoms during a single treatment is considerably higher than previously reported and may be 
exacerbated by the intake of large amounts of certain nutrients such as fiber and fat. Future 
research should examine strategies for reducing GI symptoms associated with HD treatment to 
improve patient quality of life.  
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CHAPTER 5 
INTRADIALYTIC PROTEIN SUPPLEMENTATION DOES NOT REDUCE BLOOD 
PRESSURE, TREATMENT EFFICIENCY, OR INCREASE GASTROINTESTINAL 
SYMPTOMS IN MAINTENANCE HEMODIALYSIS PATIENTS 
 
Introduction 
 Providing nutrition during hemodialysis treatment has been shown to have numerous 
benefits including the prevention of muscle catabolism [11], attenuation of treatment associated 
inflammation [9], and reductions in mortality [17, 18]. Despite these benefits, eating during 
hemodialysis treatment is frequently not allowed in clinics within the United States. A number of 
reasons have been proposed to restrict nutrition during HD treatment including intradialytic 
hypotension, increased GI symptoms, and a reduction in the efficiency with which treatment 
clears uremic solutes [19-21, 23].   
An alternative to allowing patients to eat during treatment is to allow for the consumption 
of liquid nutritional supplements. There is a perception among many clinics that liquid 
supplements would cause smaller hemodynamic alterations and, therefore, may be more suitable 
for use during HD treatment (Benner et al, in review). While liquid supplements do cause a well-
document pressor response that helps to maintain BP [86], they are also associated with more 
rapid gastric emptying which may exacerbate both the magnitude and duration of a drop in BP 
[87]. However, the effect of liquid nutritional supplements on hemodynamic variables during 
hemodialysis treatment has not yet been studied.  Therefore, the purpose of this study was to test 
the effects of a liquid protein supplement containing 30 grams of whey protein on 
hemodynamics, GI symptoms, and treatment efficiency. Given previous data showing a minimal 
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hemodynamic response to protein, we hypothesized that protein supplementation would not have 
a significant effect on blood pressure during a normal hemodialysis treatment. 
    
Methods  
As a part of a larger trial, maintenance HD patients were recruited from dialysis clinics in 
central Illinois. Patients who received HD thrice weekly, were 30-80 years old, willing to receive 
intervention, received nephrologists clearance, were not currently receiving any intradialytic 
nutrition or exercise intervention, did not have CHF or COPD, and were not allergic to milk 
proteins were enrolled. Nine HD patients met these inclusion criteria and expressed interest in 
participating in this study. One HD patient received a transplant before finishing all of the 
treatments and was dropped from the study leaving us with 8 HD patients who completed all 
treatments.  
 
Nutritional Supplement 
 Participants enrolled in the study received in a random order either: 1) standard dialysis 
session with no intervention (HD), 2) standard hemodialysis with the consumption of 30 grams 
of whey (milk) protein (HD + Protein), 3) Exercise + Protein, or 4) Exercise. For simplification, 
we have excluded the results of the exercise and exercise + protein group for this pilot study. The 
nutritional supplement was composed of 30 grams of whey protein mixed with four ounces of 
water. Nutritional analysis determined the breakdown of amino acids in the serving provided to 
patients to be 3.09 grams of leucine, 1.68 grams valine, 1.80 grams isoleucine, and 2.66 grams 
lysine. The supplement was given to patients 30 minutes into their treatment and they were asked 
to consume as much as possible in the following 15 minutes. All eight participants consumed the 
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entire study beverage. Additionally, patients underwent each of the following measurements 
during each of their treatment sessions.  
 
Hemodynamic variables 
 We measured brachial systolic blood pressure (SBP), diastolic blood pressure (DBP), and 
heart rate (HR) on the non-dialyzing arm every 15 minutes using an automated cuff built-in to 
the dialysis machine.  Measurements were taken in duplicate. If either SBP or DBP differed by 
more than 5 mm Hg, an additional measurement was taken. SBP, DBP, and HR were reported as 
the average of these measurements.  
  
Blood Draw 
Blood was drawn from the arterial line of the dialyzer prior to the start, 1.5 hours into the 
treatment, and 30 seconds after the end of the HD treatment in an EDTA plasma tube (treatment 
time varied for each patient). Blood samples were centrifuged, aliquoted, and stored at -80°C 
until the time of analysis.  
 
Treatment Efficiency 
The reduction ratio of urea (n=5) and β2-microglobulin (n=7) in the blood was 
determined in a subset of patients using the formula: ([Pre] – [Post])/[Pre] x 100). Concentrations 
of urea in the blood were determined by enzymatic assay (BioAssay Systems, Hayward, CA) and 
β2-microglobulin using a commercially available ELISA kit (abcam, Cambridge, UK).  
We also reported single pool Kt/V from online clearance measurements provided by the 
HD clinic.  In short, this is an estimate of urea removal based on the average conductivity of 
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sodium, which has a similar molecular weight, throughout the treatment. Data from one patient 
was unavailable due to a computer failure, leaving data available for seven patients.  
 
Insulin 
 Insulin concentrations were determined in a subset of patients (n=5) at each time point 
using a commercially available ELISA kit (Alpco, Salem, NH). In a few instances, duplicates fell 
off the bottom of our standard curve. In these instances we replaced those values with 0 for 
statistical analysis.  
 
Gastrointestinal Symptoms 
GI symptoms were measured using a single item 7-point Likert scale (1= No Symptoms 
to 7 = Very Severe Symptoms) that was modified from the Gastrointestinal Symptom Rating 
Scale to measure acute symptoms [88]. In short, questions asked patients about the degree to 
which they felt hunger pain, bloating, nausea, and cramps throughout each specific treatment. 
These questions were asked to patients immediately following the conclusion of each HD 
session.  
 
Statistical Analysis 
 Data are presented as mean ± standard deviation. Comparisons between treatment 
parameters, GI symptoms, efficiency variables and the lowest BP achieved between the two 
conditions were tested using a paired t-test. The number of symptomatic treatments between the 
two conditions was analyzed using a chi-square analysis. Finally, BP throughout the treatment 
was compared using nested regression (treatment nested within participant) in proc genmod 
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using SAS version 9.4 (Cary, NC). When interaction terms were non-significant main effects 
were considered.  Significance was set at an alpha of 0.05.  
 
Results 
 Eight maintenance HD patients (4 males, 4 with diabetes, age 47±13 years) were 
included in this pilot study. There were no differences in HD treatment on days where patients 
received HD or HD + Protein (Table 6). To determine the effect protein supplementation had on 
potentially vasoactive peptides, we ran plasma insulin on a subset of patients (n=5). Protein 
supplementation resulted in a numerical increase in insulin 1.5 hours into the treatment (Figure 2, 
16.61 ± 14.03 to 19.41±13.1µIU/mL in HD vs 18.28 ± 14.17 to 29.52 ± 15.141µIU/mL in HD + 
Protein) that was not statistically significant (p=0.34) 
 
Table 6.  Treatment parameters during standard hemodialysis with (HD + Protein) and without 
(HD) protein supplementation.  
  
 HD HD + Protein P –value 
Interdialytic Weight Gain (kg) 2.45 ± 1.79  3.19 ± 1.40  0.176 
Treatment Time (minutes) 225.00 ± 16.04  223.13 ± 14.87  0.351 
Ultrafiltration Volume (ml) 3,162.9 ± 1,479.0 3,265.0 ± 1,308.3  0.466 
Relative Ultrafiltration (ml/kg/hr) 8.11 ± 3.38 8.46 ± 2.65 0.387 
Dialysate Temperature (°C) 36.8 ± 0.4 36.6 ± 0. 0.285 
Blood Flow Rate (ml/min) 456.3 ± 41.7 450.0 ± 37.8 0.351 
Dialysate Flow Rate (ml/min) 725 ± 88.6 700 ± 92.6 0.170 
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Figure 2. The effect of protein on plasma insulin concentration during hemodialysis treatment.  
 
 
 
 
 
 
 
 
Plasma insulin concentrations during hemodialysis treatment with (HD + Protein) and without 
(HD) protein supplementation.  
 
 
 
 
 
There was no difference between treatments in any hemodynamic parameter at the start 
of treatment, end of treatment, or the lowest BP achieved throughout the course of a treatment 
(p>0.05 for all). Additionally, there was no interaction between the two treatment in any 
hemodynamic parameter (SBP, DBP, MAP, and HR, p>0.05). However, SBP (Figure 3a, 
p=0.047), but not MAP (Figure 3c, p=0.087) or DBP (Figure 3b, p=0.19) was reduced over the 
course of a HD treatment. Similarly, there was a significant decrease in HR over the course of 
the treatment (z = 2.65, p = 0.008).  
37 
 
Figure 3.  Blood pressure changes during hemodialysis treatment with and without protein 
supplementation.  
a. 
 
 
 
 
 
 
 
b. 
 
 
 
 
 
 
 
 
 
 
c. 
 
 
 
 
 
Systolic blood pressure (SBP), diastolic blood pressure (DBP), and mean arterial pressure (MAP) 
during hemodialysis treatments with (HD + Protein) and without (HD) protein supplementation.  
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We also examined the efficiency of solute removal (urea and β2-microglobulin) in 
sessions with and without protein supplementation (Table 7). There was no difference in the 
efficiency with which treatments removed either urea (52.5% in HD vs 55.1% in HD + Protein, 
p=0.707) or β2-microglobulin (33.4% in HD vs 28.8% in HD + Protein, p=0.671). Finally, there 
were no differences among the treatments in any measure of symptoms (Table 8).    
 
 
 
Table 7.  Efficiency of solute removal during HD treatment with and without protein 
supplementation. 
 HD HD + Protein P – Value 
Urea (n=5) 
     Pre (mg/dl) 
     Post (mg/dl) 
     Reduction Ratio (%) 
 
 
113.99 ± 22.95 
52.55 ± 14.51 
52.5 ± 14.4 
 
117.70 ± 19.79 
51.71 ± 4.99 
55.1 ± 7.8 
 
0.716 
0.893 
0.707 
spKt/V (n=7) 
 
1.42 ± 0.33 1.35 ± 0.29 0.243 
β2-Microglobulin (n=7) 
     Pre (mg/l) 
     Post (mg/l) 
     Reduction Ratio (%) 
 
33.50 ± 17.05 
21.03 ± 10.07 
33.4 ± 26.3 
 
29.88 ± 15.21 
22.70 ± 20.36 
28.8 ± 26.9 
 
0.252 
0.787 
0.671 
 
 
 
 
 
 
 
 
 
 
 
 
 
39 
 
Table 8.  Gastrointestinal Symptoms during HD treatments with and without protein 
supplementation. 
 
Symptom HD HD + 
Protein 
p-value 
Nausea 1.4±1.1 2.0±1.7 .231 
Hunger 4.0±2.3 3.1±2.2 .395 
Bloating 1.0±0.0 1.4±1.1 .356 
Cramping 2.6±2.7 2.1±2.0 .356 
Symptomatic 
(#/Total Treatments) 
2/8 2/8 - 
      Data are presented as normalized scores on a 7-point Likert scale (1 = None, 7 = Severe). 
 
 
Discussion 
In this pilot study we recruited eight maintenance HD patients and monitored 
hemodynamics, GI symptoms, and treatment efficiency during a single HD treatment with and 
without protein supplementation. While SBP and MAP were reduced over the course of a HD 
treatment, we found no difference in SBP, DBP, MAP, or HR on days with or without protein 
supplementation. In addition, solute removal (measured by the reduction ratio of β2 
microglobulin and urea) and GI symptoms did not differ between treatments. These findings 
suggest that intradialytic supplementation with 30 grams of whey protein did not lead to the 
symptoms commonly cited as a reason to restrict intradialytic nutrition.   
Intradialytic hypotension is the most common adverse event during maintenance HD 
treatment; occurring in up to 40% of all treatments [39, 89]. A common fear among renal 
clinicians is that allowing patients to consume food or nutritional supplements during treatment 
may exacerbate this problem [20, 21].  Certainly, there is a strong rationale for these concerns as 
the process of digestion has been shown to cause a reduction in total peripheral resistance (TPR), 
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especially in the splanchnic bed, a location that is a major source of vasoconstriction during the 
hypovolemic challenge of HD [58]. In healthy people, the reduction in TPR following a meal is 
compensated by an increase in cardiac output (CO) [50]. However, certain populations such as 
those with autonomic dysfunction may not produce adequate cardiac compensation, resulting in 
a drop in BP [50]. Many factors may influence the extent of this response such as meal 
composition, size, temperature, and even time of day.  In the present study, we did not observe 
an interaction in either BP or HR when we supplemented patients with whey protein alone. This 
is consistent with previous studies suggesting that protein alone causes minimal hemodynamic 
changes [90]. However, additional energy and macronutrients may improve both the palatability 
of supplements and further improve patient nutritional status. Therefore, future work should 
examine the effect of a mixed-macronutrient supplement on hemodynamic changes during HD 
treatment.  
The postprandial increase in splanchnic blood flow has also been hypothesized to reduce 
the efficiency with which a single HD treatment can remove unwanted solutes [62]. This 
phenomenon has been observed in some studies examining urea removal [60, 62]. However, urea 
removal kinetics may be complicated by the generation of urea during the digestion of protein 
[63]. In addition, urea, which is a small freely mobile molecule, may not adequately reflect the 
removal of all substances during HD [91]. Therefore, we also measured removal of the medium-
size molecule β2-microglobulin. We found no difference in the removal of either of these 
molecules during the course of a HD treatment with protein supplementation. This is perhaps not 
surprising given the lack of hemodynamic changes that we found. It remains unknown if a more 
hemodynamically challenging supplement may reduce treatment efficiency when given during 
HD treatment.   
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Similarly to IDH, GI symptoms are a common complication of HD treatment, occurring 
in approximately 10-15% of all treatments [67]. The etiology of GI symptom development 
during HD is complex, but likely includes fluid shifts, low blood pressure, and intestinal 
ischemia. These may be exacerbated by the additional metabolic demands of digestion or a 
postprandial drop in blood pressure. However, many clinicians have now argued that the 
hyperemic response to eating may prevent intestinal ischemia, maintain barrier function, and 
improve outcomes in times of hemodynamic instability [92, 93]. In the current study, we found 
no difference in the severity or prevalence of GI symptoms between HD treatment with and 
without protein supplementation. Given the etiology, it is possible that we did not see any 
difference in symptoms because we did not witness a difference in hemodynamics. Lipids have 
been implicated in causing greater metabolic demand in times of hemodynamic instability [85], 
and it remains unknown if the addition of lipid to our supplement may have caused GI distress.   
There are a number of limitations to the current trial. First, we included only eight 
participants in this pilot study. While it may be argued that the current study is underpowered to 
detect differences in the main outcomes, the effect sizes of protein supplementation are almost 
zero. Therefore, we feel it is reasonable to conclude that protein supplementation did not 
influence any of the outcomes measured in the current trial. Another limitation is that we used 
only single item Likert scales to determine the difference in symptoms between HD and HD + 
Protein. While these single items can be unreliable, this data provides a good starting point for 
future trials. Finally, our current trial lacks mechanistic data on hemodynamic changes following 
protein supplementation. Despite not having data on peripheral resistance, it seems reasonable to 
conclude that any change in TPR was minimal given the lack of changes in BP or heart rate, a 
key determinant of cardiac output.  Despite these limitations, this is the first study to examine the 
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influence of a liquid nutritional supplement consumed during HD treatment on hemodynamics, 
efficiency, and GI symptoms associated with the treatment.  
In conclusion, we did not observe any effect of 30 grams of whey protein 
supplementation during HD treatment on hemodynamics, treatment efficiency, or GI symptoms. 
These data suggest that whey protein consumed during HD treatment does not increase the 
prevalence or severity of three of the main reasons cited to restrict oral nutrition during HD 
treatment. It remains unknown what the effect of carbohydrates, lipid, or additional energy may 
be on the postprandial response during HD treatment. However, given our data intradialytic 
protein supplementation may be a feasible way to improve nutritional status in maintenance HD 
patients who can tolerate it.  
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CHAPTER 6 
THE ACUTE EFFECTS OF MIXED MACRONUTRIENT SUPPLEMENTATION 
DURING HEMODIALYSIS ON HEMODYNAMICS, TREATMENT EFFICIENCY, AND 
GASTROINTESTINAL SYMPTOMS 
 
Introduction 
 Poor nutritional status is common and among the strongest predictors of mortality in 
patients undergoing HD treatment [4-6, 34]. Reduced dietary intake, especially on treatment days 
[8], is one factor that contributes to this poor nutritional status [29]. Providing food or nutritional 
supplements during maintenance HD has been shown to help restore intake, improve nutritional 
status, and reduce mortality in malnourished patients [17, 18]. However, many clinics do not 
allow patents to eat during treatment, primarily due to concerns related to hemodynamics, 
gastrointestinal (GI) symptoms, and treatment efficiency [21].  
 Despite clinician concerns, there are very few studies examining the safety of 
intradialytic nutrition [20]. A small number of trials have found that mixed-macronutrient solid 
meals may result in a transient reduction in blood pressure (BP) (Reviewed in [20]). Therefore, a 
number of clinics have encouraged liquid supplements as opposed to solid food (Benner et al., In 
review). We previously tested the effects of a liquid protein supplement given during treatment 
and did not find any differences in hemodynamics (Chapter 5). However, simple carbohydrates 
and lipids have been shown to cause greater hemodynamic alterations [90]. Therefore, the 
purpose of this study is to determine the effect of a mixed-macronutrient liquid nutritional 
supplement on treatment hemodynamics, GI symptoms, and treatment efficiency. We 
hypothesized that this mixed-macronutrient supplement would cause a transient drop in brachial 
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blood pressure, but that the hemodynamic alteration would not be large enough to be associated 
with greater symptoms or reductions in treatment efficiency.   
 
Methods 
Participants 
We recruited 23 HD patients dialyzing at HD clinics located in central Illinois. Twelve of 
these patients met the inclusion criteria and agreed to participate. One female patient was 
dropped due to a medical issue that occurred after screening. This left us with eleven patients 
who completed the entire study protocol. Inclusion/exclusion criteria for participants included 
the following: 1) receiving thrice weekly HD; 2) received medical clearance from a Nephrologist 
at their dialysis clinic; 3) been on HD treatment for > 3 months due to physiological changes that 
typically occur at the onset of dialysis; 4) not have had hypotension requiring medical 
intervention during treatment more than four times or a hospitalization due to hypotension in the 
preceding two weeks, 5) not have a soy or milk protein allergy, and 6) not have a previous 
diagnosis of heart failure (an exclusion for physical performance testing). All patients provided 
informed consent and the trial was registered at Clinicaltrials.gov NCT02371018. 
 
Baseline Testing           
To attempt to control for fluid volume, all patients reported to the lab 18-24 hours 
following the end of their previous dialysis session for baseline testing.  During this session 
patients underwent the following testing in the order described.   
 
 
 
 
45 
 
Anthropometric measurements 
Standing height (Seca Stadiometer, Chino, CA) was determined to the nearest 0.1cm and 
weight to the nearest 0.1 kg (Tanita Corporation, Arlington Heights, IL) in duplicate with the 
participant in minimal clothing.  
 
Body composition and bone density 
Whole body fat, lean, and bone mass was measured by dual emission x-ray 
absorptiometry (DXA) (Hologic QDR 4500A, Bedford, Massachusetts). DXA scans were 
analyzed by an experienced technician blinded to the results of the acute testing sessions.  
 
Autonomic function 
 Beat-to-beat heart rate (HR) was recorded in the supine position using a modified CM5 
ECG configuration (Biopac Systems, CA) at a sampling rate of 1,000 Hz. Simultaneous beat-to-
beat peripheral BP was derived via finger plethysmography (Finometer, FMS, the Netherlands). 
Breathing frequency was maintained in all participants at a rate of 12 breaths/min (0.2 Hz) with 
the aid of a metronome. Time and frequency domains were analyzed using WinCPRS software 
(Absolute Aliens, Finland).  
  Following this baseline test, patients underwent an orthostatic challenge with free 
breathing as previously described [94]. In short, following a minute of quiet rest, patients were 
asked to come to a standing position and remain standing for 5 minutes. The blood pressure 
response during the early (immediate) and prolonged (2 minutes) standing phase as well as the 
ratio of the minimum and maximum heart rate obtained in the first thirty seconds (30:15 ratio) 
were used to screen for autonomic dysfunction as previously described [94]. Results of the 
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orthostatic challenge were used only as a screening tool, and the number of abnormal responses 
was recorded. In three patients, we were unable to obtain reliable finger waveforms and their 
data was excluded.  
 
Brachial blood pressure 
 Following a 10 minute rest, blood pressure was measured in duplicate using an automated 
cuff (Omron IntelliSense HEM-907XL, Lake Forest, IL).  If blood pressure differed by >5mmHg 
additional measures were taken following a one minute rest. Once two measurements were 
obtained, they were averaged in all subsequent analyses.  
 
Central blood pressure and wave reflection 
 Aortic blood pressure and central wave reflection were determined by tonometry using 
transformed peripheral blood pressure wave forms (measured at the radial artery) and a transfer 
function (SphygmoCor, AtCor Medical, Sydney, Australia) [95].  
 
Arterial stiffness and structure  
Aortic and femoral PWV were determined by tonometry (SphygmoCor, AtCor Medical, 
Sydney, Australia). In short, Aortic PWV was calculated as the time delay (Δt) between the R-
wave of the ECG and the foot of the forward pressure wave form (Intersecting Tangent) between 
the carotid and femoral arteries [95, 96].  The distance for the aortic PWV measurement was 
determined by subtracting the distance between the sternal notch and the location of the carotid 
pressure measurement from the distance between the sternal notch and the location of the 
47 
 
femoral pressure (distance between the femoral measurement and dorsalis pedis measurement for 
femoral PWV).  
Additionally, arterial ultrasound (Aloka, Japan) was used to determine arterial structure 
and function. Common carotid Intima Media Thickness (IMT) was determined from a segment 
10mm proximal to the carotid bifurcation as previously described [97]. β-stiffness index was 
determined in the common carotid artery using a combination of B- and M-mode. Carotid blood 
pressure obtained from tonometry was used for pressure.  
 
Cardiac ultrasound 
Cardiac dimensions and function were determined by high resolution ultrasound (Aloka, 
Japan) according to the recommendations of the American Society of Echocardiography [98]. In 
short, images were obtained in the parasternal long-axis and four-chamber views.  The 
parasternal long-axis view was used to determine left ventricular mass and volume from the 
Teichholz equation [99]. Left ventricular mass was indexed to height
2.7
 as described by de 
Simone [100]. Left ventricular volumes were indexed to body surface area. In the four chamber 
view, early and late flow in to the ventricular chamber (E and A) and tissue movement (E’) were 
measured by Doppler. We were unable to obtain quality images in two participants in the long 
axis view and their data was excluded for cardiac dimension analysis. 
 
Gait speed and shuttle walk test 
We measured the normal walking speed of each patient over a 10 meter course in 
triplicate. Following gait speed, each subject underwent an incremental shuttle walk test 
designed to assess aerobic fitness in clinical populations as previously described [9].  The 
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participants were asked to navigate a 10m course with progressively increasing speeds until they 
were unable to reach the end of the course in the allocated time. One patient did not qualify for 
the shuttle walk test due to a previous diagnosis of heart failure and they were excluded.  
 
Blood panel 
Blood collected at the dialysis clinic during normally scheduled monthly blood draws 
was assessed for standard clinical lab parameters (plasma albumin, phosphorus, calcium, etc.) by 
Spectra Laboratories, a renal specific laboratory service provider (Rockleigh, NJ).   
 
Intervention testing 
 
Starting one week following baseline testing, participants were assigned to receive each 
of the following treatments in a random order: 1) standard hemodialysis (HD); or 2) standard 
hemodialysis with the consumption of a nutrition supplement (HD + ONS). During these 
interventions participants underwent tests falling into the following categories as described 
below:  1) dietary recalls, 2) hemodynamic response, 3) gastrointestinal symptoms, 4) blood 
collection, and 5) dialysate collection.  The HD and HD + ONS testing took place during HD 
sessions on the same day of the week. Due to the potential differences caused by the prolonged 
break between treatments over the weekend, testing was not performed on participants first 
treatment of the week.  
 
Nutritional intervention 
During the session with nutrition supplementation patients received the renal specific 
nutritional supplement Nepro with Carb Steady (Abbott Nutrition, Columbus, Ohio). Patients 
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were asked to consume an 8 fl oz can of Nepro starting 30 minutes after the start of each session. 
To help control for gastric distension, the Nepro was split into two 4oz servings. The 4oz 
servings were each consumed over a 15 minute period so that the entire beverage was consumed 
by one hour into the treatment. 
 
Diet recalls   
 Patients were asked to maintain diet consistency in the 48 hours leading up to each 
testing session. Diet recalls were collected by a Registered Dietitian over the 48 hours leading up 
to each treatment (dialysis and non-dialysis day) using the USDA 5-pass method. Because the 
time since a patient last ate can influence the hemodynamic response to eating, we asked for the 
time each food item was consumed. From this temporal information, the time since a patient last 
ate was calculated. Nutrient analysis on diet recalls was performed on Nutritionist Pro software 
(Axxya, Redmond, WA).  
 
Brachial and aortic blood pressure 
 We measured brachial blood pressure and brachial wave forms to estimate aortic and 
central augmented pressure (AP) every half hour (Mobil-O-Graph, Stolberg, Germany) [101].  
 
Beat-to-beat hemodynamic monitoring: 
 Beat-to-beat BP, ECG, and thoracic bio-impedance were used to determine the 
hemodynamic response to beverage consumption. In short SBP and DBP were determined from 
beat-to-beat finger plethysmography (Task Force Monitor CN Systems, Graz, Austria). 
Transthoracic bioimpedance was used to estimate stroke volume during each beat and cardiac 
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output was reported as the product of stroke volume and heart rate from the ECG.  Total 
peripheral resistance (TPR) was calculated from the quotient of mean arterial pressure (MAP) 
and cardiac output. Measurements are reported starting 15 minutes prior to the consumption of 
the beverage and followed for the next 150 minutes. Data are reported as the average of all beats 
in each 15 minute segment. Beats that were greater than 20% different from the previous beat 
were excluded under the assumption that this was a motion artifact.  
The change in finger SBP, DBP, and MAP following administration of the beverage was 
calculated by subtracting the BP when the beverage was consumed (average of the 15 minutes 
preceding the start of supplementation) from the average of each 15 minutes segment (i.e. if the 
BP was lower than the starting BP the result would be a negative number). To determine the 
postprandial change in BP for correlation, the lowest SBP, DBP, and MAP achieved was 
subtracted from the respective value immediately prior to the administration of the supplement 
(30 minute).  
 
Gastrointestinal symptoms: 
Gastrointestinal symptoms throughout each treatment were monitored by a modified 
version of the gastrointestinal symptoms rating scale (GSRS) [81, 88].  The questionnaire has 
been modified to monitor acute ratings of GI symptoms during the HD treatment.  Briefly, 
information on three of the domains (reflux, abdominal pain, and indigestion syndrome) was 
collected at the end of each treatment (HD or HD + ONS) session.  Prior to the start of the next 
HD session (48-72 hours later), information on the other two domains (constipation, diarrhea) 
was collected for the time between treatments.   
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Blood and dialysate collection.  
  
To measure dialysis efficiency and the change in plasma proteins we drew blood 
following European Task Force Recommendations with the help of clinic nursing staff [102].  
Blood (5ml) was drawn from the dialysis line into a plasma tube containing EDTA after the 
dialysis patient was hooked up to the machine and before ultrafiltration began.  In addition 5mL 
was drawn at 1.5 hours after the start of dialysis, 3 hours after the start, and 30 seconds after the 
end of ultrafiltration at a reduced flow rate [102].  Plasma was centrifuged, aliquoted, and stored 
at -80°C until analysis.   
 
Treatment efficiency  
Urea, calcium, and phosphorus were quantified in the blood using an autoanalyzer 
(Abaxis Piccolo Xpress, Union City, CA) [103].  β2-microglobulin was determined by 
commercially available ELISA (Abcam, Cambridge, MA). Changes in urea, β2-microglobulin, 
and phosphorus were measured by the ratio of removal (Equation 1) with the concentration of 
urea replaced by the concentration of the solute of interest.   
 
Equation 1.  URR = (PreHDUrea – PostHDurea)/PreHDUrea  [104] 
 
Blood glucose 
 A small amount of blood (<0.5mL) was collected at 0, 30, 60, 90, 120, 180 and the end of 
each treatment from the arterial line. From these samples, blood glucose concentrations were 
determined in duplicate by the glucose oxidase method [105, 106].  
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Insulin 
Insulin concentrations were determined in duplicate (n=7) from blood samples at 0, 90, 
and 180 minutes by a commercially available ELISA kit (Alpco, Salem, NH).   
 
Treatment parameters 
 Dialysate composition, temperature, ultrafiltration rate and total volume, interdialytic 
weight gain, pre- and post-treatment weight, time on treatment, blood flow rate, dialysate flow 
rate, and other factors that may influence the outcomes of the intervention were collected for 
analysis. All patients were undergoing hemodialysis with high-flux polysulfone dialyzers 
(Fresenius). 
 
Statistical Analysis:  
Statistical analyses was performed using SAS statistical software version 9.3 (Cary, NC) 
with significance set at p<0.05.  Difference between dialysis treatment parameters, efficiency 
variables, pre-treatment BP, post-treatment BP, lowest BP, and gastrointestinal symptoms were 
compared by paired t-test. The number of treatments requiring medical intervention 
(administration of saline) was compared by a chi-square test. The association of treatment 
parameters, cardiac structure, and cardiac function with changes in BP was examined by Pearson 
correlation.      
To compare how hemodynamic variables changed during treatments, repeated measures 
were modeled with treatment nested within subject in SAS using proc mixed. When interaction 
terms were non-significant main effects were considered.  When the model indicated a 
significant interaction, differences between treatments were determined by LSD.  
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Results 
Patient demographics and baseline testing 
A description of the 11 participants who finished the study (Table 9) and their baseline 
arterial (Table 10), cardiac (Table 11), and autonomic function (Table 12) are presented in tables 
on the following pages.    
 
Table 9. Participant characteristics.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Measure Value 
Age (y) 47 ± 13 
Ethnicity (n, %) 
     African American 
     Caucasian  
     Hispanic 
 
7 (63.6) 
3 (27.3) 
1 (9.1) 
Sex (n, %) 
     Male 
     Female 
 
8 (72.7) 
3 (27.3) 
Albumin (g/dl) 4.06 ± 0.35 
Height (cm) 167.9 ±6.7 
Weight (kg) 94.3 ± 21.6 
Waist:Hip 0.99 ± 0.11 
Whole Body Percent Fat (%) 32.4 ± 11.4 
Bone Mineral Density (g/cm) 1.18 ± 0.10 
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Table 10. Measures of arterial structure and function.    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
SBP = systolic blood pressure, DBP = diastolic blood pressure, bpm = beats per minute, IMT = 
intima media thickness 
 
 
 
 
 
 
 
Measure Value 
Brachial SBP (mmHg) 144.1 ± 16.5 
Brachial DBP (mmHg) 79.2 ± 11.8 
Aortic SBP (mmHg) 128.4 ± 14.6 
Aortic DBP (mmHg) 80.8 ± 12.0 
Aortic Pulse Pressure (mmHg) 47.5 ± 11.5 
Heart Rate (bpm) 76.5 ± 6.3 
Augmented Pressure (mmHg) 10.4 ± 7.2 
Augmentation Index @ 75bpm (%) 21.1 ± 10.9 
Aortic Pulse Wave Velocity (m/s) 9.0 ± 1.1 
Femoral Pulse Wave Velocity (m/s) 9.6 ± 1.8 
β-Stiffness Index (AU) 8.2 ± 4.5 
Carotid IMT (mm) 0.62 ± 0.13 
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Table 11. Measures of cardiac structure and function.  
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Measure Value 
Left Ventricular Mass (g/m
2.7
) 
      Hypertrophy (n, %) 
84.11 ± 18.59 
      (9,100) 
Left Atrial Volume (ml) 
     Normally Dilated (22-58) 
     Mildly Dilated (59-68) 
     Moderately Dilated (69-78) 
     Severely Dilated (>79) 
41.55 ± 12.86 
     9 
     1 
     1 
     0 
End Diastolic Volume Index (ml/m
2
) 65.87 ± 17.73 
End Systolic Volume Index (ml/m
2
) 26.87 ± 14.39 
Stroke Volume Index (ml/m
2
) 39.40 ± 12.33 
Cardiac Output Index (l/min/m
2
) 2.92 ± 0.83 
Ejection Fraction (%) 
     ≥55 (n) 
     40-54.9 
     <40 
61.13 ± 15.59 
     6 
     2  
     1 
E/A  1.21 ± 0.48 
E/E’ 10.17 ± 4.88 
A Duration (s) 0.136 ± 0.043 
Deceleration Time (s) 0.194 ± 0.033 
Left Ventricular Diastolic Dysfunction (%) 63.6% 
56 
 
Table 12. Baseline autonomic function in patients undergoing HD.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
BRS = baroreceptor sensitivity, LF = Low frequency, HF = High frequency 
 
 
Conditions associated with each treatment 
In order to monitor how well patients adhered to our request to maintain diet, we 
monitored dietary intake over the 48 hours preceding each test. We found no difference in the 
time since a patient had eaten or in the intake of any nutrients between the two groups (Table 
13). Additionally, we found no difference in any hemodynamically relevant parameters 
associated with each treatment (Table 14). 
Measure Value 
R – R Interval (ms) 794.8 ± 68.0 
pNN50 (%) 6.52 ± 10.06 
Ln Total Power  5.97 ± 1.89 
Ln Low Frequency  4.54 ± 2.23 
Low Frequency (nu) 54.2 ± 18.3 
Ln High Frequency  4.30 ± 2.34 
High Frequency (nu) 42.6 ± 17.9 
LF/HF 1.80 ± 1.48 
30:15 Ratio  1.13 ± 0.09 
BRS Up (ms/mmHg) 7.01 ± 5.42 
BRS Down (ms/mmHg) 9.30 ± 7.08 
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Table 13. Difference in average dietary intake over the 48 hours prior to HD or HD + ONS 
trials.  
 HD HD + ONS p – value  
Time since last meal 
(minutes) 
473.8 ± 240.8 491.8 ± 282.0 0.366 
Energy (kcal) 1811.66 ± 574.97 2055.48 ± 477.09 0.185 
Protein (g) 69.46 ± 33.30 83.76 ± 29.74 0.063 
Carbohydrate (g) 223.54 ± 78.87 255.59 ± 84.69 0.295 
Fat (g) 65.26 ± 27.80 78.62 ± 18.33 0.203 
Sodium (mg) 2768.78 ± 1292.67 3455.94±1033.13 0.091 
 
 
Table 14. Treatment parameters for HD and HD + ONS trials.  
 HD HD + ONS P - value 
Interdialytic Weight 
Gain (kg) 
2.25 ± 0.82 2.48 ± 0.90 0.410 
Start Weight (kg) 96.66 ± 22.11 96.70 ± 22.03 0.910 
End Weight (kg) 93.48 ± 22.01 93.72 ± 21.68 0.264 
Ultrafiltration (ml) 2924.55 ± 1056.71 3061.00 ± 634.52 0.689 
Relative UF rate 
(ml/kg/min) 
8.29 ± 3.01 8.77 ± 2.15 0.602 
Blood Flow Rate 
(ml/min) 
454.55 ± 35.03 454.55 ± 35.03 1.00 
Dialysate Flow Rate 
(ml/min) 
709.09 ± 70.06 681.82 ± 75.08 0.277 
Saline (n) 2 2 1.00 
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Changes in vasoactive substances 
To determine the influence of HD and HD + ONS on potentially vasoactive substances in 
the blood, we measured blood glucose and insulin throughout the treatment. There was a trend 
for an increase in blood glucose in HD + ONS (Figure 4a, F1,20 = 3.94, p = 0.061). Similarly, there 
was a numerical increase in postprandial insulin (Figure 4b) in the HD + ONS group, but this 
was not significant (F1,12 = 0.38, p = 0.550).  
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Figure 4. Changes in vasoactive substances during a standard hemodialysis treatment with and 
without an oral nutrition supplement.   
 
a. 
 
 
 
 
 
 
 
 
 
b. 
 
 
 
  
 
 
 
 
Figure 4. Changes in plasma glucose (n = 11) (a) and insulin (n = 7) (b) during a standard 
hemodialysis treatment (HD) and HD in which patients consumed a liquid mixed-macronutrient 
supplement 30 minutes into treatment (HD + ONS). There was a trend for an increase in blood 
glucose in the HD + ONS (p=0.06), but no other interactions or main effects (p > 0.05).  
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Changes in brachial and aortic hemodynamics 
To determine the effect of HD and HD + ONS on central hemodynamics we monitored 
brachial pulse wave forms intermittently throughout each treatment. We found no differences in 
any hemodynamic variables at the start of treatment on HD and HD + ONS day (p>0.05). There 
was no change in brachial SBP (Figure 5a, F1,18 = 0.03, p = 0.876), brachial DBP (Figure 5b, 
F1,18 = 0.83, p = 0.375), aortic SBP (Figure 6a, F1,18 = 0.11, p = 0.741), aortic DBP (Figure 6b, 
F1,18 = 1.17, p = 0.294), AP (F1,18 = 0.17, p = 0.681), or systemic vascular resistance (Figure 7, 
F1,18 = 1.03, p = 0.323) between groups. Furthermore, when we compared the lowest BP 
achieved during the treatment, we found no difference in either brachial SBP (127.9 ± 20.51 
mmHg in HD vs 121.6 ± 12.65 mmHg in HD + ONS, p = 0.341) or brachial DBP (76.5 ± 12.75 
mmHg in HD vs 76.6 ± 12.88 mmHg in HD + ONS, p = 0.977).  
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Figure 5. Changes in brachial systolic blood pressure (SBP) and diastolic blood pressure during 
a standard hemodialysis treatment with and without an oral nutritional supplement.  
a. 
 
 
 
 
 
 
 
 
 
b. 
 
 
 
 
 
 
 
 
Figure 5. Changes in brachial systolic blood pressure (SBP) (a) and brachial diastolic blood 
pressure (DBP) (b) during a standard hemodialysis treatment (HD) and HD in which patients 
consumed a liquid mixed-macronutrient supplement 30 minutes into treatment (HD + ONS). 
There were no interactions or main effects (p > 0.05).  
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Figure 6. Changes in aortic systolic blood pressure (SBP) and diastolic blood pressure during a 
standard hemodialysis treatment with and without an oral nutritional supplement. 
a. 
 
 
 
 
 
 
 
 
b. 
 
 
 
 
 
 
 
 
 
Figure 6. Changes in aortic systolic blood pressure (SBP) (a) and aortic diastolic blood pressure 
(DBP) (b) during a standard hemodialysis treatment (HD) and HD in which patients consumed a 
liquid mixed-macronutrient supplement 30 minutes into treatment (HD + ONS). There were no 
interactions or main effects (p > 0.05).  
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Figure 7. Changes in systemic vascular resistance during HD treatment with and without ONS.  
 
 
 
 
 
 
 
 
 
 
Figure 7. Changes in systemic vascular resistance during a standard hemodialysis treatment (HD) 
and HD in which patients consumed a liquid mixed-macronutrient supplement 30 minutes into 
treatment (HD + ONS). There were no interactions or main effects (p > 0.05).  
 
 
 
Beat-to-beat postprandial hemodynamic changes 
 To determine the hemodynamic changes associated with the consumption of the study 
beverage, we monitored beat-to-beat hemodynamics for 150 minutes following the consumption 
of the study beverage. We found no difference in the change in SBP (Figure 8a, F1,20 = 0.25, p = 
0.621), DBP (Figure 8b, F1,20 = 0.02, p = 0.880), TPR (Figure 9a, F1,20 = 0.01, p = 0.914), or CO 
(Figure 9b, F1,20 = 0.19, p = 0.667). However, a main effect did exist for CO (F1,20 = 4.85, p = 
0.040) to be elevated following the ONS supplementation, primarily due to an increase in heart 
rate (F1,20 = 4.38, p = 0.049). 
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Figure 8. Postprandial change in beat-to-beat blood pressure with and without ONS during HD 
treatment.  
a. 
 
 
 
 
 
 
 
 
b. 
 
 
 
 
 
 
 
 
 
Figure 8. Changes in beat-to-beat systolic blood pressure (SBP) (a) and diastolic blood pressure 
(DBP) (b) during a standard hemodialysis treatment (HD) and HD in which patients consumed a 
liquid mixed-macronutrient supplement 30 minutes into treatment. There were no interactions or 
main effects (p > 0.05).  
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Figure 9. Changes in total peripheral resistance and cardiac output with and without ONS during 
HD treatment.  
a. 
 
 
 
 
 
 
 
 
 
b. 
 
 
 
 
 
 
 
 
 
Figure 9. Changes in total peripheral resistance (a) and cardiac output (b) during a standard 
hemodialysis treatment (HD) and HD in which patients consumed a liquid mixed-macronutrient 
supplement 30 minutes into treatment. There were no interactions (p > 0.05), but a significant 
main effect of treatment existed for the change in cardiac output (p = 0.04).  
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Figure 10. Postprandial change in heart rate and stroke volume during HD treatment with and 
without ONS.   
a. 
 
 
 
 
 
 
 
 
 
b. 
 
 
 
 
 
 
 
 
 
 
Figure 10. Changes in heart rate (a) and stroke volume (b) during a standard hemodialysis 
treatment (HD) and HD in which patients consumed a liquid mixed-macronutrient supplement 30 
minutes into treatment. There were no interactions (p > 0.05), but a significant main effect of 
treatment existed for the change in heart rate (p = 0.05).  
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Solute removal 
 We measured the removal of a number of solutes over the course of a HD treatment with 
and without ONS. There was no difference in the reduction ratio of the medium-sized molecule 
β2-microglobulin or in the final concentration (Table 15). We also found no difference in 
estimated urea removal (spKt/V) by online clearance (p = 0.351).   
 
 
Table 15. No difference in solute removal during HD and HD + ONS.  
Solute Standard 
Hemodialysis 
Nutrition 
Supplementation 
P-Value 
Single Pool Kt/V 1.73 1.65 0.351 
β2-Microglobulin 
      Pre (mg/l) 
      Post (mg/l) 
      Reduction Ratio (%) 
 
29.46 ± 12.03 
14.88 ± 7.28 
48.97 ± 18.62 
 
27.67 ± 13.29 
16.08 ± 6.56 
37.89 ± 15.63 
 
0.459 
0.505 
0.250 
 
 
 
 
 
 
Gastrointestinal symptoms 
 To determine the effect of ONS on GI symptom development associated with a single 
treatment, we administered a modified version of the GSRS following each treatment. There was 
no difference between the severity of GI symptoms in any domain between HD and HD + ONS 
(Table 16).  
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Table 16. No difference in standardized gastrointestinal scores for HD and HD + ONS trials.  
Scale Standard 
Hemodialysis 
Nutrition 
Supplementation 
P-Value 
Abdominal Pain 1.36 ± 0.53 1.39 ± 0.57 0.878 
Reflux Syndrome 1.09 ± 0.30 1.05 ± 0.15 0.676 
Indigestion Syndrome 1.42 ± 0.70 1.27 ± 0.61 0.450 
Diarrhea Syndrome 1.39 ± 0.55 1.70 ± 0.85 0.308 
Constipation Syndrome 1.18 ± 0.17 1.48 ± 0.70 0.148 
 
 
 
 
 
 
 
 
 
 
 
Relationship between descriptive variables and changes in BP 
 To determine the relationship between the changes in BP following ONS and underlying 
CV structure and function, we correlated select CV and treatment variables with the maximum 
change in BP following beverage consumption (Table 17). The only variable correlated with the 
change in BP was baroreceptor sensitivity.  
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Table 17. Associations between descriptive variables and the change in blood pressure following 
the consumption of the study beverage.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   p < 0.05* 
 
 
 
 
 
 
 
Variable  Delta SBP 
(mmHg) 
Delta DBP 
(mmHg) 
Delta  MAP 
(mmHg) 
Age (y) -.193 -.073 -.274 
Albumin (g/dl) .389 .237 .422 
Relative Ultrafiltration 
Rate (ml/kg/min) 
-.122 -.428 -.242 
Shuttle Walk Test .224 .220 .318 
Augmentation Index @ 
75bpm (%) 
-.447 -.379 -.451 
Aortic PWV (m/s) .266 -.436 -.059 
IMT (mm) -.251 -.421 -.440 
LF/HF -.163 -.337 -.237 
BRS Up (ms/mmHg) .439 .847* .676 
BRS Down (ms/mmHg) .790* .347 .706* 
Ejection Fraction (%) .087 -.455 -.196 
Left Atrial Volume (ml) .325 .089 .172 
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Discussion 
 In the current study, we compared hemodynamics, GI symptoms, and treatment 
efficiency during a standard HD treatment and a standard HD treatment in which patients 
consumed a mixed-macronutrient liquid supplement. After ONS, cardiac output and heart rate 
were significantly higher during HD + ONS, but there were no other significant hemodynamic 
changes. Despite the higher cardiac output, we saw no difference between HD or HD + ONS in 
any measure of GI symptoms or treatment efficiency. When we attempted to determine risk 
factors for a postprandial drop during HD treatment, only baseline BRS was correlated with the 
maximum drop in BP following the consumption of the study beverage. 
 Despite the benefits, many clinics within the United States do not allow patients to eat 
during HD treatment due to concerns about hemodynamic stability [19-21]. Previous trials on 
this topic have focused exclusively on solid, mixed-macronutrient meals and produced equivocal 
hemodynamic results [20]. However, many clinics have more lenient policies towards liquid 
nutritional supplements. Despite these more lenient policies these supplements have been 
sparsely evaluated. We previously found that a liquid supplement containing 30 grams of whey 
protein did not result in any significant hemodynamic alterations (Kistler et al., In prep (Chapter 
5)). Given that simple carbohydrates appear to be the primary cause of postprandial reductions in 
BP, in this trial we tested the effects of a mixed-macronutrient supplement formulated 
specifically for HD patients. However, similar to our findings with whey protein, we found no 
reduction in any measure of BP.  
 The postprandial hemodynamic response is complicated and dependent on many factors 
including gastric emptying, cardiovascular function, and meal composition [107]. In patients 
who suffer a postprandial drop in BP there is generally an inadequate response to a drop in 
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systemic vascular resistance (SVR) brought about by a meal [50]. It may be hypothesized that 
this response may be exacerbated by the challenge of HD treatment, especially given that eating 
would reduce SVR in vascular beds that tend to constrict in response to hypovolemia [58]. In the 
current trial, we did not find a significant reduction in SVR in the HD + ONS compared to the 
HD treatment. One reason for the equivocal hemodynamic results in the current trial may be the 
modified maltodextrin added to this specific ONS supplement to slow intestinal absorption and 
reduce the postprandial spike in blood glucose [108]. This would minimize the early arrival of 
simple carbohydrates such as glucose which appear to be responsible for majority of the BP drop 
after eating [107]. However, a number of mechanistic questions remain unanswered including 
the effect of nutritional supplements on local environments, especially those that are prone to 
ischemic damage during HD treatment such as the heart, brain, and intestine.  
 Allowing patients to eat during HD treatment has also been hypothesized to contribute to 
the development of GI symptoms [21]. One way in which food may contribute to GI symptoms 
is through the potential postprandial reduction in BP [39]. Low BP during HD treatment has been 
linked to ischemic damage of many organ systems such as the heart and the brain [109]. The 
intestine is another organ prone to ischemic damage in kidney disease patients, especially those 
undergoing HD [79, 110]. In the present study, we measured aortic pressure and central 
augmented pressure which may better estimate the environment being experienced by central 
organs. One reason we may not have seen a change in any of the GI symptom domains is the 
lack in change in these pressures. Despite these data, providing nutrition in times of 
hemodynamic instability remains controversial due to the increased metabolic demand of the 
intestine and mucosal barrier at a time when perfusion is reduced [93, 111]. However, most 
studies appear to show that the increase in blood flow during digestion leads to improved 
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oxygenation, barrier function, and outcomes [85, 93, 111]. In the present study, we did not 
measure the local hyperemic response, however, the potential role intradialytic nutrition 
supplementation may play on gut health is an important target of future research.  
 An additional concern has been raised about the role digestion may have on the ability of 
HD to remove unwanted solutes. It has been hypothesized that increasing the amount of blood in 
the digestive tract may reduce the blood available to interact with the dialyzer [62]. Previous 
trials on eating during treatment have produced mixed results [60-62], although these studies 
may be confounded by the effects of protein digestion on urea kinetics [63]. Therefore, in the 
current trial we measured the removal of additional solutes less likely to be influenced by the 
process of digestion. When we looked at these additional markers, we found no difference in any 
measure of solute removal between treatments with and without ONS. These results coincide 
with those of our previous surveys, which found that this is not a problem frequently observed in 
clinical practice [21]. 
 Finally, we hoped to identify the potential relationship between the change in BP 
following ONS and cardiovascular structure and function. Of the cardiovascular and treatment 
parameters we tested, only baseline baroreceptor sensitivity was significantly associated with the 
maximum drop in BP. This is consistent with previous studies that have associated reduced 
baroreceptor function with the postprandial drop in BP [50]. Impaired autonomic function is 
common in HD patients due to a variety of comorbidities that include diabetic and uremic 
neuropathy, hypotension, arterial stiffness, and issues with systemic nitric oxide [112]. Future 
studies should examine more thoroughly the relationship between autonomic function and 
postprandial blood pressure in HD patients.   
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 In conclusion, we found that providing ONS during HD treatment did not reduce any 
measure of BP throughout the treatment. Although we did not find changes in BP, we did find a 
significant increase in CO and HR over the 150 minutes following supplementation.  Despite 
these hemodynamic alterations we found no increase in GI symptoms or reduction in treatment 
efficiency. Similar to previous studies on postprandial hemodynamics, we found baroreceptor 
sensitivity to be related to the maximum drop in BP following the beverage. Future research 
should determine if patients with reduced autonomic function may be at increased risk of a 
postprandial drop in BP during HD treatment and the effect of nutrition supplementation on gut 
barrier function. However, the current trial does not support the practice of restricting nutrition 
during HD treatment.  
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CHAPTER 7 
CONCLUSIONS 
 Maintenance HD is a catabolic condition associated with poor nutritional status. 
Providing nutrition during HD improves nutritional status and outcomes. However, this practice 
is controversial due to concerns that include hemodynamic instability, GI distress, and reduced 
treatment efficiency. There is a lack of data on the proposed harms associated with eating during 
treatment, and this has led to clinic practices that differ drastically throughout organizations, 
regions, and the world.  
 Therefore, we set out to use a combination of survey and interventional research to 
provide clinicians with data on the relative frequency and severity of the proposed harms 
associated with eating during treatment. Our survey results indicated that with the exception of 
GI symptoms and hypotension, most of the concerns related to eating during treatment were not 
frequently observed in clinical practice. Furthermore, GI symptom severity was not greater in 
patients who ate during treatment versus those who did eat during treatment. However, certain 
nutrients, specifically fiber and fat, may be associated with greater indigestion in large amounts. 
 When we performed randomized crossover trials using liquid supplements that contained 
protein or combinations of the three macronutrients, we found no difference in blood pressures 
throughout the treatment, symptoms associated with the treatment, or the removal of solutes by 
the treatment. However, we did find significantly higher cardiac output following a renal specific 
mixed-macronutrient supplement. The maximum drop in blood pressure following the 
consumption of the supplement was associated with baseline baroreceptor sensitivity, but no 
other aspect of cardiovascular structure or function. Although additional research is needed to 
help develop guidelines, these data do not seem to support the current practice in the United 
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States of restricting patients from eating during maintenance HD treatment. Future research 
should focus on identifying patients at risk of a postprandial drop in BP, the effects of nutrition 
supplementation on tissues prone to ischemic damage such as the heart and brain, and to further 
document the benefits of intradialytic nutrition, especially in patients who may not be classified 
as malnourished.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
76 
 
REFERENCES 
 
1. Kalantar-Zadeh, K., et al., Appetite and inflammation, nutrition, anemia, and clinical 
outcome in hemodialysis patients. Am J Clin Nutr, 2004. 80(2): p. 299-307. 
2. Shinaberger, C.S., et al., Longitudinal associations between dietary protein intake and 
survival in hemodialysis patients. Am J Kidney Dis, 2006. 48(1): p. 37-49. 
3. Kalantar-Zadeh, K. and J.D. Kopple, Obesity paradox in patients on maintenance 
dialysis. Contrib Nephrol, 2006. 151: p. 57-69. 
4. Kalantar-Zadeh, K., et al., Revisiting mortality predictability of serum albumin in the 
dialysis population: time dependency, longitudinal changes and population-attributable 
fraction. Nephrol Dial Transplant, 2005. 20(9): p. 1880-8. 
5. Rambod, M., et al., Association of serum prealbumin and its changes over time with 
clinical outcomes and survival in patients receiving hemodialysis. Am J Clin Nutr, 2008. 
88(6): p. 1485-94. 
6. Rambod, M., et al., Association of Malnutrition-Inflammation Score with quality of life 
and mortality in hemodialysis patients: a 5-year prospective cohort study. Am J Kidney 
Dis, 2009. 53(2): p. 298-309. 
7. Kalantar-Zadeh, K., et al., Dietary restrictions in dialysis patients: is there anything left 
to eat? Semin Dial, 2015. 28(2): p. 159-68. 
8. Burrowes, J.D., et al., Effects of dietary intake, appetite, and eating habits on dialysis and 
non-dialysis treatment days in hemodialysis patients: cross-sectional results from the 
HEMO study. J Ren Nutr, 2003. 13(3): p. 191-8. 
9. Tomayko, E.J., et al., Intradialytic protein supplementation reduces inflammation and 
improves physical function in maintenance hemodialysis patients. J Ren Nutr, 2014. 
10. Ikizler, T.A., et al., Hemodialysis stimulates muscle and whole body protein loss and 
alters substrate oxidation. Am J Physiol Endocrinol Metab, 2002. 282(1): p. E107-16. 
11. Pupim, L.B., et al., Intradialytic oral nutrition improves protein homeostasis in chronic 
hemodialysis patients with deranged nutritional status. J Am Soc Nephrol, 2006. 17(11): 
p. 3149-57. 
12. Veeneman, J.M., et al., Protein intake during hemodialysis maintains a positive whole 
body protein balance in chronic hemodialysis patients. Am J Physiol Endocrinol Metab, 
2003. 284(5): p. E954-65. 
13. Caglar, K., et al., Therapeutic effects of oral nutritional supplementation during 
hemodialysis. Kidney Int, 2002. 62(3): p. 1054-9. 
14. Milano, M.C., et al., Energy supplementation in chronic hemodialysis patients with 
moderate and severe malnutrition. J Ren Nutr, 1998. 8(4): p. 212-7. 
15. Calegari, A., et al., Malnourished patients on hemodialysis improve after receiving a 
nutritional intervention. J Bras Nefrol, 2011. 33(4): p. 394-401. 
16. Dong, J., et al., The effect of resistance exercise to augment long-term benefits of 
intradialytic oral nutritional supplementation in chronic hemodialysis patients. J Ren 
Nutr, 2011. 21(2): p. 149-59. 
17. Weiner, D.E., et al., Oral intradialytic nutritional supplement use and mortality in 
hemodialysis patients. Am J Kidney Dis, 2013. 
77 
 
18. Lacson, E., Jr., et al., Outcomes associated with intradialytic oral nutritional supplements 
in patients undergoing maintenance hemodialysis: a quality improvement report. Am J 
Kidney Dis, 2012. 60(4): p. 591-600. 
19. Kalantar-Zadeh, K. and T.A. Ikizler, Let them eat during dialysis: An overlooked 
opportunity to improve outcomes in maintenance hemodialysis patients. J Ren Nutr, 
2013. 23(3): p.157-163. 
20. Kistler, B.M., et al., Rethinking the restriction on nutrition during hemodialysis 
treatment. J Ren Nutr, 2014. 25(2): p. 81-87. 
21. Kistler, B., et al., To eat or not to eat-International experiences with eating during 
hemodialysis treatment. J Ren Nutr, 2014. 24(6): p. 349-352. 
22. Foley, R.N. and R.M. Hakim, Why is the mortality of dialysis patients in the United 
States much higher than the rest of the world? J Am Soc Nephrol, 2009. 20(7): p. 1432-5. 
23. Kalantar-Zadeh, K., et al., Diets and enteral supplements for improving outcomes in 
chronic kidney disease. Nat Rev Nephrol, 2011. 7(7): p. 369-84. 
24. Christner, H. and M. Riley, Should patients eat during hemodialysis treatments? Nephrol 
Nurs J, 2008. 35(2): p. 203-4. 
25. Kinnel, K., Should patients eat during hemodialysis treatments? Nephrology Nursing 
Journal 2005. 32(5): p. 513-515. 
26. Kalantar-Zadeh, K., Why not meals during dialysis? , in Renal and Urology News2009: 
New York. 
27. Franch, H.A., Nutrition and muscle catabolism in maintenance hemodialysis: does 
feeding make muscle cells selective self-eaters? J Ren Nutr, 2009. 19(1): p. 86-90. 
28. Kalantar-Zadeh, K., et al., The obesity paradox and mortality associated with surrogates 
of body size and muscle mass in patients receiving hemodialysis. Mayo Clin Proc, 2010. 
85(11): p. 991-1001. 
29. Fouque, D., et al., A proposed nomenclature and diagnostic criteria for protein-energy 
wasting in acute and chronic kidney disease. Kidney Int, 2008. 73(4): p. 391-8. 
30. Pupim, L.B., et al., Accelerated lean body mass loss in incident chronic dialysis patients 
with diabetes mellitus. Kidney Int, 2005. 68(5): p. 2368-74. 
31. Kim, J.C., K. Kalantar-Zadeh, and J.D. Kopple, Frailty and protein-energy wasting in 
elderly patients with end stage kidney disease. J Am Soc Nephrol, 2013. 24(3): p. 337-51. 
32. Feroze, U., et al., Quality-of-life and mortality in hemodialysis patients: roles of race and 
nutritional status. Clin J Am Soc Nephrol, 2011. 6(5): p. 1100-11. 
33. Lacson, E., Jr., et al., Potential impact of nutritional intervention on end-stage renal 
disease hospitalization, death, and treatment costs. J Ren Nutr, 2007. 17(6): p. 363-71. 
34. Kovesdy, C.P. and K. Kalantar-Zadeh, Why is protein-energy wasting associated with 
mortality in chronic kidney disease? Semin Nephrol, 2009. 29(1): p. 3-14. 
35. Avram, M.M., et al., Predictors of survival in continuous ambulatory peritoneal dialysis 
patients: the importance of prealbumin and other nutritional and metabolic markers. Am 
J Kidney Dis, 1994. 23(1): p. 91-8. 
36. Clinical practice guidelines for nutrition in chronic renal failure. K/DOQI, National 
Kidney Foundation. Am J Kidney Dis, 2000. 35(6 Suppl 2): p. S1-140. 
37. Sehgal, A.R., J. Leon, and J.A. Soinski, Barriers to adequate protein nutrition among 
hemodialysis patients. J Ren Nutr, 1998. 8(4): p. 179-87. 
78 
 
38. Burrowes, J.D., et al., Effects of dietary intake, appetite, and eating habits on dialysis and 
non-dialysis treatment days in hemodialysis patients: cross-sectional results from the 
HEMO study. J Ren Nutr, 2003. 13(3): p. 191-8. 
39. Davenport, A., Intradialytic complications during hemodialysis. Hemodial Int, 2006. 
10(2): p. 162-7. 
40. Davenport, A., C. Cox, and R. Thuraisingham, Achieving blood pressure targets during 
dialysis improves control but increases intradialytic hypotension. Kidney Int, 2008. 
73(6): p. 759-64. 
41. Boon, D., et al., Blood pressure response to uncomplicated hemodialysis: the importance 
of changes in stroke volume. Nephron Clin Pract, 2004. 96(3): p. c82-7. 
42. Bos, W.J., et al., Cardiac and hemodynamic effects of hemodialysis and ultrafiltration. 
Am J Kidney Dis, 2000. 35(5): p. 819-26. 
43. Henderson, L.W., Symptomatic intradialytic hypotension and mortality: an opinionated 
review. Semin Dial, 2012. 25(3): p. 320-5. 
44. Lai, C.T., et al., Absolute interdialytic weight gain is more important than percent weight 
gain for intradialytic hypotension in heavy patients. Nephrology (Carlton), 2012. 17(3): 
p. 230-6. 
45. Xu, Y., et al., Hypertension, fluid overload and micro inflammation are associated with 
left ventricular hypertrophy in maintenance hemodialysis patients. Ren Fail, 2013. 
46. Shoji, T., et al., Hemodialysis-associated hypotension as an independent risk factor for 
two-year mortality in hemodialysis patients. Kidney Int, 2004. 66(3): p. 1212-20. 
47. Dinesh, K., et al., A model of systolic blood pressure during the course of dialysis and 
clinical factors associated with various blood pressure behaviors. Am J Kidney Dis, 
2011. 58(5): p. 794-803. 
48. Lipsitz, L.A., et al., Hemodynamic and autonomic nervous system responses to mixed 
meal ingestion in healthy young and old subjects and dysautonomic patients with 
postprandial hypotension. Circulation, 1993. 87(2): p. 391-400. 
49. Jansen, R.W. and L.A. Lipsitz, Postprandial hypotension: epidemiology, 
pathophysiology, and clinical management. Ann Intern Med, 1995. 122(4): p. 286-95. 
50. Luciano, G.L., M.J. Brennan, and M.B. Rothberg, Postprandial hypotension. Am J Med, 
2010. 123(3): p. 281 e1-6. 
51. Benaroia, M. and E.A. Iliescu, Oral intake during hemodialysis: is there an association 
with intradialytic hypotension? Hemodial Int, 2008. 12(1): p. 62-5. 
52. Strong, J., et al., Effects of calorie and fluid intake on adverse events during 
hemodialysis. J Ren Nutr, 2001. 11(2): p. 97-100. 
53. Sherman, R.A., F. Torres, and R.P. Cody, Postprandial blood pressure changes during 
hemodialysis. Am J Kidney Dis, 1988. 12(1): p. 37-9. 
54. Zoccali, C., et al., Postprandial alterations in arterial pressure control during 
hemodialysis in uremic patients. Clin Nephrol, 1989. 31(6): p. 323-6. 
55. Liang, C.S. and J.M. Lowenstein, Metabolic control of the circulation. Effects of acetate 
and pyruvate. J Clin Invest, 1978. 62(5): p. 1029-38. 
56. Shibagaki, Y. and K. Takaichi, Significant reduction of the large-vessel blood volume by 
food intake during hemodialysis. Clin Nephrol, 1998. 49(1): p. 49-54. 
57. Barakat, M.M., et al., Hemodynamic effects of intradialytic food ingestion and the effects 
of caffeine. J Am Soc Nephrol, 1993. 3(11): p. 1813-8. 
79 
 
58. Daugirdas, J.T., Dialysis hypotension: a hemodynamic analysis. Kidney Int, 1991. 39(2): 
p. 233-46. 
59. Muller-Deile, J., et al., Online Kt/V monitoring in haemodialysis by UV absorbance: 
Variations during intra-dialytic meals. Blood Purif, 2014. 37(2): p. 113-118. 
60. Kara, B. and C.H. Acikel, The effect of intradialytic food intake on the urea reduction 
ratio and single-pool Kt/V values in patients followed-up at a hemodialysis center. 
Turkish Journal of Medical Sciences, 2010. 40(1): p. 91-97. 
61. Singri, N., et al., Effect of predialysis eating on measurement of urea reduction ratio and 
Kt/V. Adv Chronic Kidney Dis, 2004. 11(4): p. 398-403. 
62. San Juan Miguelsanz, M., S.M. Pilar, and M.R. Santos de Pablos, Reduction of Kt/V by 
food intake during haemodialysis. EDTNA/ERCA journal (English ed ), 2001. 27(3): p. 
150-2. 
63. Polaschegg, H.D., Letter to the editor. J Ren Care, 2009. 35(2): p. 108. 
64. Strid, H., et al., The prevalence of gastrointestinal symptoms in patients with chronic 
renal failure is increased and associated with impaired psychological general well-being. 
Nephrol Dial Transplant, 2002. 17(8): p. 1434-9. 
65. Hammer, J., et al., Chronic gastrointestinal symptoms in hemodialysis patients. Wien 
Klin Wochenschr, 1998. 110(8): p. 287-91. 
66. Van Vlem, B., et al., Delayed gastric emptying in dyspeptic chronic hemodialysis 
patients. Am J Kidney Dis, 2000. 36(5): p. 962-8. 
67. Dumler, F., et al., Clinical experience with short-time hemodialysis. Am J Kidney Dis, 
1992. 19(1): p. 49-56. 
68. Skroeder, N.R., et al., Biocompatibility of dialysis membranes is of no importance for 
objective or subjective symptoms during or after hemodialysis. ASAIO Trans, 1990. 
36(3): p. M637-9. 
69. Collins, D.M., et al., Tolerance of hemodialysis: a randomized prospective trial of high-
flux versus conventional high-efficiency hemodialysis. J Am Soc Nephrol, 1993. 4(2): p. 
148-54. 
70. Sezer, S., et al., Long-term oral nutrition supplementation improves outcomes in 
malnourished patients with chronic kidney disease on hemodialysis. JPEN J Parenter 
Enteral Nutr, 2014. 38(8): p. 960-965.  
71. Scott, M.K., et al., Effects of Peridialytic Oral Supplements on Nutritional Status and 
Quality of Life in Chronic Hemodialysis Patients. Journal of Renal Nutrition, 2009. 
19(2): p. 145-152. 
72. Pupim, L.B., et al., Intradialytic parenteral nutrition improves protein and energy 
homeostasis in chronic hemodialysis patients. J Clin Invest, 2002. 110(4): p. 483-92. 
73. Scott, M.K., et al., Effects of peridialytic oral supplements on nutritional status and 
quality of life in chronic hemodialysis patients. J Ren Nutr, 2009. 19(2): p. 145-52. 
74. Benner, D., et al., Practices And Opinions On In-Center Food Consumption Across 1,223 
Facilities In The United States. Kidney Research and Clinical Practice, 2012. 31(2): p. 
A60. 
75. Combe, C., et al., Kidney Disease Outcomes Quality Initiative (K/DOQI) and the Dialysis 
Outcomes and Practice Patterns Study (DOPPS): nutrition guidelines, indicators, and 
practices. Am J Kidney Dis, 2004. 44(5 Suppl 2): p. 39-46. 
76. Franch, H. and K. Kalantar-Zadeh, World Renal Nutrition Week Congress: from Hawaii 
to Germany. J Ren Nutr, 2013. 23(3): p. 194. 
80 
 
77. Jansen, R.W., et al., The effect of oral glucose, protein, fat and water loading on blood 
pressure and the gastrointestinal peptides VIP and somatostatin in hypertensive elderly 
subjects. Eur J Clin Invest, 1990. 20(2): p. 192-8. 
78. Dong, R., et al., Gastrointestinal symptoms: a comparison between patients undergoing 
peritoneal dialysis and hemodialysis. World J Gastroenterol, 2014. 20(32): p. 11370-5. 
79. Yasuhara, H., Acute mesenteric ischemia: the challenge of gastroenterology. Surg Today, 
2005. 35(3): p. 185-95. 
80. Gliem, J. and R. Gliem, Calculating, interpreting, and reporting cronbach’s alpha 
reliability coefficient for likert-type scales, in Midwest Research to Practice Conference 
in Adult, Continuing, and Community Education2003: The Ohio State University, 
Columbus. 
81. Revicki, D.A., et al., Reliability and validity of the Gastrointestinal Symptom Rating 
Scale in patients with gastroesophageal reflux disease. Qual Life Res, 1998. 7(1): p. 75-
83. 
82. Hoaglin, D.C., B. Iglewicz, and J.W. Tukey, Performance of some resistant rules for 
outliers. Journal of the american statistical association, 1986. 81: p. 991-999. 
83. Babka, J.C., G.W. Hager, and D.O. Castell, The effect of body position on lower 
esophageal sphincter pressure. Am J Dig Dis, 1973. 18(5): p. 441-2. 
84. Marlett, J.A., et al., Position of the American Dietetic Association: health implications of 
dietary fiber. J Am Diet Assoc, 2002. 102(7): p. 993-1000. 
85. Crissinger, K.D. and P. Tso, The role of lipids in ischemia/reperfusion-induced changes 
in mucosal permeability in developing piglets. Gastroenterology, 1992. 102(5): p. 1693-9. 
86. Jones, K.L., et al., Effects of drink volume and glucose load on gastric emptying and 
postprandial blood pressure in healthy older subjects. Am J Physiol Gastrointest Liver 
Physiol, 2005. 289(2): p. G240-8. 
87. Jones, K.L., et al., Rate of gastric emptying is a determinant of postprandial hypotension 
in non-insulin-dependent diabetes mellitus. Clin Sci (Lond), 1998. 94(1): p. 65-70. 
88. Svedlund, J., I. Sjodin, and G. Dotevall, GSRS--a clinical rating scale for gastrointestinal 
symptoms in patients with irritable bowel syndrome and peptic ulcer disease. Dig Dis 
Sci, 1988. 33(2): p. 129-34. 
89. Davenport, A., C. Cox, and R. Thuraisingham, Blood pressure control and symptomatic 
intradialytic hypotension in diabetic haemodialysis patients: a cross-sectional survey. 
Nephron Clin Pract, 2008. 109(2): p. c65-71. 
90. Ferreira-Filho, S.R., et al., Systemic hemodynamic changes in elderly hypertensive 
patients after ingesting foods with lipid, protein, and carbohydrate contents. J Clin 
Hypertens (Greenwich), 2009. 11(5): p. 271-6. 
91. Leypoldt, J.K., et al., Kinetics of urea and beta-microglobulin during and after short 
hemodialysis treatments. Kidney Int, 2004. 66(4): p. 1669-76. 
92. Flordelis Lasierra, J.L., J.L. Perez-Vela, and J.C. Montejo Gonzalez, Enteral nutrition in 
the hemodynamically unstable critically ill patient. Med Intensiva, 2015. 39(1): p. 40-8. 
93. Zaloga, G.P., P.R. Roberts, and P. Marik, Feeding the hemodynamically unstable patient: 
a critical evaluation of the evidence. Nutr Clin Pract, 2003. 18(4): p. 285-93. 
94. Wieling, W. and J.M. Karemaker, Measurement of heart rate and blood pressure to 
evaluate disturbances in neurocardiovascular control, in Autonomic Failure, C.J. 
Mathias and R. Bannister, Editors. 1999, Oxford University Press: Great Britain. 
81 
 
95. Laurent, S., et al., Expert consensus document on arterial stiffness: methodological issues 
and clinical applications. Eur Heart J, 2006. 27(21): p. 2588-605. 
96. Van Bortel, L.M., et al., Clinical applications of arterial stiffness, Task Force III: 
recommendations for user procedures. Am J Hypertens, 2002. 15(5): p. 445-52. 
97. Fahs, C.A., et al., Acute effects of firefighting on arterial stiffness and blood flow. Vasc 
Med, 2011. 16(2): p. 113-8. 
98. Cheitlin, M.D., et al., ACC/AHA/ASE 2003 guideline update for the clinical application 
of echocardiography--summary article: a report of the American College of 
Cardiology/American Heart Association Task Force on Practice Guidelines 
(ACC/AHA/ASE Committee to Update the 1997 Guidelines for the Clinical Application of 
Echocardiography). J Am Coll Cardiol, 2003. 42(5): p. 954-70. 
99. Teichholz, L.E., et al., Problems in echocardiographic volume determinations: 
echocardiographic-angiographic correlations in the presence of absence of asynergy. 
Am J Cardiol, 1976. 37(1): p. 7-11. 
100. de Simone, G., et al., Left ventricular mass and body size in normotensive children and 
adults: assessment of allometric relations and impact of overweight. J Am Coll Cardiol, 
1992. 20(5): p. 1251-60. 
101. Sarafidis, P.A., et al., Evaluation of a novel brachial cuff-based oscillometric method for 
estimating central systolic pressure in hemodialysis patients. Am J Nephrol, 2014. 40(3): 
p. 242-50. 
102. Transplantation, E.E.G.o.R., European best practice guidelines for hemodialysis (Part 1). 
Nephrol Dial Transplant, 2002. 17: p. S17-S23. 
103. Murata, K., et al., Analytical performance of the Abaxis Piccolo Xpress(R) point of care 
analyzer in whole blood, serum, and plasma. Clin Biochem, 2015. 
104. Owen, W.F., Jr., et al., The urea reduction ratio and serum albumin concentration as 
predictors of mortality in patients undergoing hemodialysis. N Engl J Med, 1993. 
329(14): p. 1001-6. 
105. Middleton, J.E., Experience with a glucose-oxidase method for estimating glucose in 
blood and C. S. F. Br Med J, 1959. 1(5125): p. 824-6. 
106. Ferrario, M., et al., Effects of dialysate glucose concentration on heart rate variability in 
chronic hemodialysis patients: results of a prospective randomized trial. Kidney Blood 
Press Res, 2011. 34(5): p. 334-43. 
107. Berry, M.K., et al., Effect of solid meal on gastric emptying of, and glycemic and 
cardiovascular responses to, liquid glucose in older subjects. Am J Physiol Gastrointest 
Liver Physiol, 2003. 284(4): p. G655-62. 
108. Wolf, B.W., et al., Glycemic response to a food starch esterified by 1-octenyl succinic 
anhydride in humans. J Agric Food Chem, 2001. 49(5): p. 2674-8. 
109. McIntyre, C.W., et al., Hemodialysis-induced cardiac dysfunction is associated with an 
acute reduction in global and segmental myocardial blood flow. Clin J Am Soc Nephrol, 
2008. 3(1): p. 19-26. 
110. Shi, K., et al., Gut bacterial translocation may aggravate microinflammation in 
hemodialysis patients. Dig Dis Sci, 2014. 59(9): p. 2109-17. 
111. Yang, S., et al., Early enteral nutrition in critically ill patients with hemodynamic 
instability: an evidence-based review and practical advice. Nutr Clin Pract, 2014. 29(1): 
p. 90-6. 
82 
 
112. Kotanko, P., Cause and consequences of sympathetic hyperactivity in chronic kidney 
disease. Blood Purif, 2006. 24(1): p. 95-9. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
83 
 
APPENDIX 
 
Acute gastrointestinal symptoms questionnaire (Day 1) 
To be given immediately following HD treatment 
The following questions ask about whether you experienced stomach or intestinal 
discomfort during your dialysis treatment. Please circle your response for each 
question. 
1. Were you bothered by stomach pain during the treatment that just ended?  
(Stomach pain refers to all kinds of aches or pains in your stomach or belly) 
1 2 3 4 5 6 7 
No 
Discomfort 
Slight 
Discomfort 
Mild 
Discomfort 
Moderate 
Discomfort 
Moderately 
Severe 
Discomfort 
Severe 
Discomfort 
Very Severe 
Discomfort 
 
2. Were you bothered by heartburn during the treatment that just ended?  
(Heartburn refers to the burning pain or discomfort behind the breastbone in 
your chest) 
1 2 3 4 5 6 7 
No 
Discomfort 
Slight 
Discomfort 
Mild 
Discomfort 
Moderate 
Discomfort 
Moderately 
Severe 
Discomfort 
Severe 
Discomfort 
Very Severe 
Discomfort 
 
3. Were you bothered by acid reflux during the treatment that just ended?  (Acid 
reflux refers to regurgitation or flow of sour or bitter fluid into your mouth) 
1 2 3 4 5 6 7 
No 
Discomfort 
Slight 
Discomfort 
Mild 
Discomfort 
Moderate 
Discomfort 
Moderately 
Severe 
Discomfort 
Severe 
Discomfort 
Very Severe 
Discomfort 
 
4. Were you bothered by nausea during the treatment that just ended? (Nausea 
refers to a feeling of wanting to be sick) 
1 2 3 4 5 6 7 
No 
Discomfort 
Slight 
Discomfort 
Mild 
Discomfort 
Moderate 
Discomfort 
Moderately 
Severe 
Severe 
Discomfort 
Very Severe 
Discomfort 
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Discomfort 
 
5. Were you bothered by hunger pains during the treatment that just ended? 
(Hunger pains refers to the hollow feeling in the stomach is associated with the 
need to eat between meals) 
1 2 3 4 5 6 7 
No 
Discomfort 
Slight 
Discomfort 
Mild 
Discomfort 
Moderate 
Discomfort 
Moderately 
Severe 
Discomfort 
Severe 
Discomfort 
Very Severe 
Discomfort 
 
6. Were you bothered by rumbling in your stomach during the treatment that just 
ended?  (Rumbling refers to the vibrations or noise in the stomach) 
1 2 3 4 5 6 7 
No 
Discomfort 
Slight 
Discomfort 
Mild 
Discomfort 
Moderate 
Discomfort 
Moderately 
Severe 
Discomfort 
Severe 
Discomfort 
Very Severe 
Discomfort 
 
7. Were you bothered by burping during the treatment that just ended?  (Burping 
refers to bringing up air or gas through the mouth) 
1 2 3 4 5 6 7 
No 
Discomfort 
Slight 
Discomfort 
Mild 
Discomfort 
Moderate 
Discomfort 
Moderately 
Severe 
Discomfort 
Severe 
Discomfort 
Very Severe 
Discomfort 
 
8. Were you bothered by bloating during the treatment that just ended? (By 
bloating we mean swelling in the stomach) 
1 2 3 4 5 6 7 
No 
Discomfort 
Slight 
Discomfort 
Mild 
Discomfort 
Moderate 
Discomfort 
Moderately 
Severe 
Discomfort 
Severe 
Discomfort 
Very Severe 
Discomfort 
 
9. Were you bothered by gas or flatus during the treatment that just ended?  
(Passing gas or flatus refers to the release of air or gas from the bowel) 
1 2 3 4 5 6 7 
No 
Discomfort 
Slight 
Discomfort 
Mild 
Discomfort 
Moderate 
Discomfort 
Moderately 
Severe 
Discomfort 
Severe 
Discomfort 
Very Severe 
Discomfort 
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Acute gastrointestinal symptoms questionnaire (Day 2) 
To be given 48-72 hours after the previous HD treatment 
The following questions ask about whether you experienced stomach or intestinal 
discomfort after your previous dialysis treatment. Please circle your response for 
each question. 
 
1. Have you been bothered by constipation since your previous hemodialysis 
treatment?  (Constipation refers to a reduced ability to empty your bowels) 
1 2 3 4 5 6 7 
No 
Discomfort 
Slight 
Discomfort 
Mild 
Discomfort 
Moderate 
Discomfort 
Moderately 
Severe 
Discomfort 
Severe 
Discomfort 
Very Severe 
Discomfort 
 
2. Have you been bothered by diarrhea since your previous hemodialysis 
treatment?  (Diarrhea refers to frequent loose or watery stools) 
1 2 3 4 5 6 7 
No 
Discomfort 
Slight 
Discomfort 
Mild 
Discomfort 
Moderate 
Discomfort 
Moderately 
Severe 
Discomfort 
Severe 
Discomfort 
Very Severe 
Discomfort 
 
3. Have you been bothered by loose stools since your previous hemodialysis 
treatment? (If your stools have been alternately hard and loose, this question 
only refers to the extent to which you have been bothered by your stools being 
loose) 
1 2 3 4 5 6 7 
No 
Discomfort 
Slight 
Discomfort 
Mild 
Discomfort 
Moderate 
Discomfort 
Moderately 
Severe 
Discomfort 
Severe 
Discomfort 
Very Severe 
Discomfort 
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4. Have you been bothered by hard stools since your previous hemodialysis 
treatment? (If your stools have been alternately hard and loose, this question 
only refers to the extent to which you have been bothered by your stools being 
hard) 
1 2 3 4 5 6 7 
No 
Discomfort 
Slight 
Discomfort 
Mild 
Discomfort 
Moderate 
Discomfort 
Moderately 
Severe 
Discomfort 
Severe 
Discomfort 
Very Severe 
Discomfort 
 
5. Have you been bothered by an urgent need to have a bowel movement since 
your last hemodialysis treatment?  (This urgent need to open your bowels 
makes you rush to the toilet). 
1 2 3 4 5 6 7 
No 
Discomfort 
Slight 
Discomfort 
Mild 
Discomfort 
Moderate 
Discomfort 
Moderately 
Severe 
Discomfort 
Severe 
Discomfort 
Very Severe 
Discomfort 
 
6. When going to the toilet since your last hemodialysis treatment, have you had a 
feeling of not completely emptying your bowels?  (The feeling that after a 
bowel movement, there is still more stool that needs to be passed) 
1 2 3 4 5 6 7 
No 
Discomfort 
Slight 
Discomfort 
Mild 
Discomfort 
Moderate 
Discomfort 
Moderately 
Severe 
Discomfort 
Severe 
Discomfort 
Very Severe 
Discomfort 
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